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Chapter 1 Introduction 
"The people who bind themselves to systems are those who 
are unable to encompass the whole truth and try to catch it by 
a tail; a system is like the tail of truth, but the truth is like a 
lizard; it leaves its tail in your fingers and runs away knowing 
full well that it will grow a new one in a twinkling" 
-Ivan Turgenev· 
1.1. Introduction 
c 
ardiovascular disease remains one of the most important causes of 
morbidity and mortality in Western society, especially as the average age 
of the population increases 1• Heart failure is clinical syndrome which may 
develop as a consequence of both peripheral and cardiac disorders 
(hypertension, aortic stenosis, cardiomyopathy, myocardial infarction), and is 
recognized clinically by a constellation of various signs and symptoms produced by 
complex circulatory and neurohormonal responses to cardiac dysfunction. Heart 
failure as a consequence of myocardial infarction is rapidly becoming one of the most 
prevalent cardiovascular disorders and the incidence of heart failure is expected to 
continue to increase for some time to come. The prognosis of heart failure is poor 2 
and the economic impact of heart failure on health services is considerable because 
of the long-term pharmacological treatment and frequent hospitalizations associated 
with the syndrome 3• 
Our conceptualization of heart failure is constantly evolving. Once considered a 
simple problem of left ventricular pump dysfunction, heart failure has now come to 
be understood as a highly complex clinical syndrome that is manifested by many 
extracardiac features, including neuroendocrine activation. The hemodynamic 
hypothesis has largely been abandoned, and embracement of the neurohormonal 
hypothesis has resulted in extraordinary changes in the clinical management of 
patients with chronic heart failure. A more contempory working hypothesis is that 
heart failure is a progressive disorder of neurohormonal activation and left ventricular 
remodeling, usually resulting from an index event, that culminates in a clinical 
syndrome characterized by impaired cardiac function and circulatory congestion (Fig 
1). 
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Index Event -
Acute myocardial infarction 
Gene mutation 
Acute inflammation 
Onset of hypertension 
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Rbrosis, chamber dilation 
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Increasing symptoms 
Fig.l Working hypothesis of heart failure (Francis GS, 2001) 
New therapies are now evolving that are designed to modulate cardiac remodeling by 
inhibition of neuroendocrine as well as cytokine activation and matrix 
metalloprote"inases, whereas drugs designed to heighten cardiac contractility have 
proven to be unhelpful in long-term management of heart failure. The modern 
treatment of chronic heart failure is now largely based on the neurohormonal 
hypothesis, which states that neuroendocrine activation and associated structural 
remodeling is important in the progression of heart failure and that inhibition of 
neurohormones is likely to have long-term benefit with regard to morbidity and 
mortality. 
1.2. Pathophysiology of postinfarction induced heart failure 
The consequence of a sustained segmental interruption of coronary blood fiow 
to the myocardium, such as coronary artery occlusion is myocardial infarction. Loss 
of contractile tissue after myocardial infarction can severly affect pump function of 
the left ventricle, mainly depending on the magnitude of myocardial necrosis 4 • Large 
infarcts (>40%) lead to severe cardiac dysfunction, resulting in sudden cardiac death 
or chronic heart failure. In contrast, smaller infarctions may be initially associated 
with only minor alterations of hemodynamic parameters because of compensatory 
mechanisms. Acute myocardial infarction evokes activation of several mechanisms to 
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compensate for acute loss of function. Three major neurohormonal systems are 
activated to preserve tissue perfusion: 
l. Sympathetic nervous system activity 
2. Renin-angiotensin-aldosterone system 
3. Arginine-vasopressin 
Immediately activated mechanisms are sustained by neurohormonal activation, which 
is followed by a structural response of the heart. All structural alterations in cardiac 
architecture, at organ as well as at tissue and cellular level, are referred to as 
myocardial 'remodeling'. Although cardiac remodeling occurs as a structural 
response to the increased hemodynamic load on the surviving myocardium, it may 
finally contribute to the development of heart failure. Several stages of postinfarction 
remodeling have been described. The early comoensatorv phase is followed by a 
more stable compensated phase which is characterized by a (partly) restored cardiac 
output but with decreasec left ventricular function and ejection fraction. When 
symptoms of heart failure become overt, a decompensation phase develops driven by 
the same mechanisms as the compensation phase, but with a very poor prognosis. In 
Fig.3 an overview of major peripheral and cardiac mechanisms involved in the 
pathophysiology of heart failure is given. 
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Fig.3 Peripheral and cardiac adaptation as a compensatory 
response to left ventricular dysfunction. 
The different aspects of neuroendocrine activation and postinfarction remodeling as 
well as their possible role in the transition from postinfarction left ventricular 
dysfunction towards heart failure will be discussed more in detail in the following part 
of the thesis. 
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1.3. Neurohormonal activation 
Several neurohormones are activated after myocardial infarction, the 
magnitude and time course of which are closely related to infarct size and degree of 
LV dysfunction 5• The neurohormonal hypothesis postulates that neurohormones are 
initially adaptive by maintaining cardiac output and blood pressure, but later the 
same compensatory responses become pathological and contribute to adverse 
remodeling, progressive ventricular failure, and ultimately to the syndrome of heart 
failure 6• 
1.3.1. Sympathetic nervous system 
The first compensatory mechanism involved in heart failure is increased 
activity of the sympathetic nervous system, which act to maintain blood pressure 
when cardiac performance is initially depressed. This is achieved by stimulation of 
myocardial B·adrenoceptors (inotropic stimulation) and of vascular a-adrenoceptors 
which increase venous return and arterial resistance. Although activation of 
neurohormonal compensatory mechanisms may appear beneficial and adaptive to 
preserve blood pressure and cardiac output, excessive and prolonged sympathetic 
stimulation negatively affects the prognosis of heart failure 7• 
Norepinephrine is an important but rather insensitive marker of mortality. 
Patients dying from progressive myocardial pump function failure have shown to 
display rapid progressively increasing norepinephrine levels 8 Increased 
norepinephrine levels in heart failure are caused by increased norepinephrine 
spillover and decreased uptake. Adverse actions of high plasma catecholamines levels 
include trophic and toxic effects on cardiac myocytes 9, downregulation of ~ 1-
adrenoceptors, increased renin secretion and myocardial as well as vascular 
hypertrophy 10•11• Cytotoxicity of catecholamines may also be related to oxidative-
related damage since catecholamines are metabolized partly through oxidation. In 
addition, sympathetic stimulation after myocardial infarction causes myocardial 
oxygen demand to rise, precipitating further ischemia, and the proarryhtmic effects 
of catecholamines may predispose to fatal arrythmias 9• 
13 
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Sympathetic stimulation increases myocardial energy consumption and can 
promote ischemia especially at the level of subendocardial cells of a dilated ventricle. 
Increased energy consumption at the cellular level is induced since more actin-
myosin cross-bridging between myofibrils has to occur during each cardiac cycle. The 
higher level of cross-bridging activity is achieved by an increase in calcium delivery to 
the myofibrils, which is pumped back either by the sarcoplasmatic reticulum or into 
the extracellular space by sarcolemma calcium pumps and sodium-calcium exchange 
12
. Furthermore, sympathetic stimulation increases intracellular concentrations of 
cAMP and calcium which could promote myocyte deterioration and apoptosis. 
1.3.2. Renin-angiotensin-aldosterone system 
Sympathetic-dependent vasoconstriction induces a reduction in the capacity of 
the kidney to excrete excess sodium 13• During the initial stages of heart failure, 
symptoms of sodium retention only occur in cases of excessive intake of sodium. As 
the disease progresses, sodium retention remains constant through the stimulation of 
the renin-angiotensin-aldosterone system, this being the second major compensatory 
mechanism. The release of renin increases indirectly with reduction in renal artery 
pressure, and directly by sympathetic tone via B1·adrenoceptors. The combined 
stimulation of sympathetic and renin-angiotensin-aldosterone systems acts to 
maintain blood pressure through vasoconstriction and plasma volume expansion. 
Thus, sodium retention appears to be a key condition in heart failure. Plasma 
hormonal profiles have been studied extensively during heart failure. Initially the 
levels of plasma catecholamines are elevated during mild heart failure, with plasma 
renin activity increasing at later and more severe stages of the disease (Studies of 
Left Ventricular Dysfunction; SOLVD study) 14. Consequences of such a renin-
angiotensin stimulation are first, increased cardiac loading conditions 
(vasoconstriction), and second, cellular actions of angiotensin II through activation of 
phospholipase C, especially stimulation of cell growth and of collagen synthesis by 
fibroblasts. Furthermore, physiological actions of angiotensin II include inotropic and 
chronotropic effects on the myocardium 1s, and effects on cardiovascular growth. 
14 
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Aldosterone production is stimulated by angiotensin II and enhances sodium 
re-absorption by the distal tubule of the kidney. Some experimental work 
demonstrated that administration of high doses of aldosterone to rats and guinea 
pigs induces perivascular and interstitial collagen synthesis 16• Such effects may 
promote the replacement of contractile fibers by fibrous tissue and further alter 
cardiac function: ventricle enlargement, arrythmias and ischemia by increasing the 
distance between capillaries and contractile sites of myocytes. 
1.3.3. Arginine-vasopressin 
The role of vasopressin system in the development of heart failure as well as 
the therapeutic possibilities of vassopressin antagonists are less investigated. 
Arginine-vasopressin is secreted by the posterior pituitary gland and is an antidiuretic 
hormone, and its two principal hemodynamic effects, vasoconstriction and fluid 
retention, are mediated via the V1aand v, receptors, respectively 17•18• Vasopressin is 
involved in regulation of circulating volume and osmolarity and has a suppressive 
effect on renin release by renal juxtaglomerulary cells 19• Its secretion is stimulated 
by ~-adrenergic activation and angiotensin II. Vasopressin has direct vasoconstrictive 
effects and indirect facilitating effects on sympathetic nervous system in an animal 
model 20 • Through activation of specific vasopressin \2- receptors, vasopressin has 
some vasodilating action as well 21 • Overall, vasoconstrictive action prevails. 
Currently, there are only a limited number of studies examining the use of 
vasopressin antagonists as therapy for heart failure. Selective inhibition of the V1 and 
v, receptor led to immediate improvement in hemodynamic parameters 22 and 
increased diuresis 23 . 
1.4. Postinfarction remodeling 
When neurohormonal activation is not capable to restore hemodynamics after 
acute myocardial infarction, cardiac loading conditions remain increased evolving 
structural adaptation of the heart itself. This complex of structural changes is termed 
remodeling 24• The cardiac remodeling process tends to reconstitute myocardial 
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tissue mass and to restore normal cardiovascular hemodynamics after large 
myocardial infarction 25• Postinfarction remodeling has been divided into an early 
compensatorv phase and late decompensation phase. Whereas in the early phase 
irreversibly damaged tissue is replaced by scar tissue and compensatory changes 
(myocyte hypertrophy) occur in the non-infarcted myocardium, late phase involves a 
continued remodeling process not accompanied by improved cardiac function and 
even contributing to progression of left ventricular dysfunction. 
Initially, cardiac remodeling can be viewed as a compensatory mechanism 
(normalizing wall stress), which provides a functional advantage. However, at some 
point, these regenerative responses may become deleterious and contribute to heart 
failure 26.27 • It has become increasingly recognized that besides infarct size, the 
quality of the remaining viable tissue is a key determinant in ultimate patient 
prognosis. The acute loss of myocardium after myocardial infarction results in an 
abrupt increase in loading conditions that induces a unique pattern of remodeling 
involving the infarcted border zone and remote non-infarcted myocardium. Myocyte 
necrosis and the resultant increase in load trigger a cascade of biochemical 
intracellular signaling processes that initiates and subsequently modulates reparative 
changes, which include dilation, hypertrophy, and the formation of a discrete 
collagen scar. Ventricular remodeling may continue until the distending forces are 
counterbalanced by the tensile strength of the collagen network. This balance is 
determined by the size, location, and transmurality of the infarct, the extent of 
myocardial stunning, the patency of the infarct-related artery, and local tropic factors 
24
•
28
• The failure to normalize increased wall stresses results in progressive dilation, 
recruitment of border zone myocardium into the scar, and deterioration in contractile 
function. Three major components of the myocardium following myocardial infarction 
are involved in the remodeling process: myocytes, extracellular matrix, and capillary 
microcirculation that services the contractile unit assembly. Consideration of all 3 
components provides important insights into remodeling process and a rationale for 
future therapeutic strategies. 
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1.4.1. Infarcted myocardium 
During the first hours after myocardial infarction, a reparative process is 
initiated to rebuild infarcted myocardium and maintain structural integrity of the 
ventricle. The repair process of the heart after myocardial infarction is considered a 
wound healing response, since it resembles the response of parenchymatous tissue 
to ischemic injury. In the infarcted area, myocyte necrosis and an acute inflammatory 
response at the border of the necrotic myocytes take place, followed by 
inflammation, fibroblast- and vascular cell proliferation, extracellular matrix 
deposition and resorption of necrotic tissue. Inflammatory response to cell death 
after myocardial infarction becomes evident by cellular infiltration (neutrophils 
followed by lymphocytes and plasma cells) progressing from the border zone into the 
more central areas of the infarct 29• Other signs of inflammation are present, such as 
interstitial oedema and vascular congestion. 
More recently, it was suggested that myocyte programmed cell death or 
apoptosis was the major initial, as early as 2 hours after infarct induction, form of 
myocyte loss produced by coronary artery occlusion in rats, whereas necrotic cell 
death followed apoptosis and contributed to the evolution of the infarct size 30• 
Apoptosis was largely limited to hypoxic regions during acute infarction. Also in 
human infarcts extensive apoptosis occurred before neutrophilic infiltration was 
apparent. During the healing phase of the infarction, apoptosis has been reported to 
play an important role in the disappearance of infiltrated leucocytes 31• 
Changes in collagen metabolism in the infarct segment have been subject of 
detailed investigation in the rat infarction model. Early after infarction degradation of 
the collagenous network surrounding cardiomyocytes and capillaries in the infarct 
zone occurs 32• Collagen fibers are broken down by the activation of collagenases and 
related enzymes. The breakdown of cardiac structure can lead to slippage of 
surviving myocytes and, in addition, to myocyte loss. This process may cause 
disproportionate dilation and thinning of the infarct, also called 'infarct expansion' 33• 
Infarct expansion is a risk factor for the development of ventricular aneurysm or even 
rupture and is associated with adverse effects on ventricular function and prognosis 
34
. Scar formation is the net result of a delicate balance between collagen 
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degradation and synthesis 35• In infarcted rats, the expression of type I collagen gene 
is markedly enhanced in the infarcted zone on day 3 and pers·ISts for 90 days 32•36 • 
Fibrillar collagen deposition was observed by day 7 35• Collagen degradation exceeds 
synthesis during the very early phase of infarction. Enhanced collagen degradation 
after myocardial infarction involves a family of matrix metalloproteinases which 
mediate degradation of fibrillar collagen 37• In turn, the activity of metalloproteinases 
is controlled by a family of tissue inhibitors of metalloproteinases. Thus, the balance 
between collagenases and tissue inhibitors of metalloproteinases ultimately 
determines the amount of collagenolysis in infarcted tissue 32• 
Myofibroblasts have been shown to be the predominant cell responsible for 
collagen formation at sites of repair in the rat heart 32•36 . These myofibroblasts were 
shown to remain in mature scar tissue 38• Increases of both types I and III 
procollagen mRNA levels have been observed within a few days after infarct 
induction, followed by collagen deposition 32 . The amount of other constituents of the 
extracellular matrix, such as fibronectin and tenascin, also changes after the 
induction of myocardial infarction 39•40 . 
1.4.2. Non-infarcted myocardium 
At first sight the changes in the non-infarcted myocardium are not as dramatic 
as the changes in the infarct. Changes in the non-infarcted myocardium, however, 
affect both ventricles and affect all constituents of the myocardium, including the 
cardiomyocytes, vasculature as well as the extracellular matrix. 
Myocyte hypertrophy 
Compensation for the loss of viable tissue after infarction entails myocyte 
hypertrophy in the non-infarcted myocardium 41 • cardiomyocyte hypertrophy occurs 
within several days after infarction and cardiomyocytes may increase their volume up 
to 112% in humans 42• In cardiomyocytes, DNA synthesis is a limited process and 
involves less than 1% of the DNA synthetizing cells in rats 43•44• Hypertrophy early 
after infarction may be seen as an useful adjustement to loss of contractile tissue, by 
increasing the number of sarcomeres and by restoring wall stress in the infarcted 
18 
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ventricle 41 • In infarcted rats, side-to-side slippage of ventricular myocytes occurs in 
the first days after infarction and contributes to left ventricular enlargement 42• After 
the acute phase, eccentric hypertrophy of myocytes further expands the left ventricle 
45
• Besides eccentric hypertrophy, concentric growth of myocytes occurs in the non-
infarcted part of the injured left ventricle. Reactive hypertrophy can be considered as 
an adequate response, though not always sufficient to normalize cardiac load. 
Besides through hypertrophy, myocardial mass may also increase through an 
increase in cell number. For a long time the prevailing perception has been that 
cardiomyocytes are terminally differentiated cells and lose their ability to proliferate. 
Myocytes lose the ability to divide shortly after birth 46, although myocyte polyploidy 
through nuclear division has been reported in hypertrophied hearts 47•48 and even the 
possibility of myocyte hyperplasia 42• 
Cardiomyocyte apoptosis is also an important process which has been 
described in the non-infarcted myocardium, and may contribute to the remodeling 
process after infarction 49, and to the induction or progression of cardiac failure after 
infarction 50• Indeed, a significant increase in myocyte apoptosis could be observed in 
the human failing heart 51. Not only cell size and number, but also the cellular 
phenotype may change. Cardiac hypertrophy secondary to infarction is associated 
with altered gene expression, especially genes of the fetal phenotype 52• For 
example, a transition of the expression of the normally expressed fast contractile 
protein o:-myosin heavy chain to the slower ~-myosin heavy chain results in a 
decreased capacity to develop contractile speed 52•53• Such a change can be viewed 
to be adaptive because of a lower energy and oxygen consumption of the cardiac 
muscle. 
Extracellular matrix 
The extracellular matrix forms the structural backbone of the heart and is 
composed of a complex of macromolecules, which can be divided in at least five 
major components: collagens, basement membranes, elastic fibers, proteoglycans 
and structural glycoproteins. The collagen network is major constituent for the 
preservation of myocardial architecture and chamber geometry and plays an integral 
role in global ventricular remodeling 54• Interstitial collagens I and III, which are 
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predominantly produced by fibroblasts, form the major components of the 
extracellular matrix 55 • An early accumulation of fibrillar collagen in the non-infarcted 
region has repeatedly been observed following infarction 43•56. This increase in 
collagen seems not to be directly related to myocyte necrosis, but resembles the 
pattern of reactive fibrosis, characterized by thickening of the perimysium and 
occupation of intermuscular spaces by collagen fibers 32• The elevation of collagen 
content in the non-infarcted septum is preceded by a 4 to 5-fold increased 
production of type I and III procollagen mRNA until 21 days post-infarction 32• The 
stimulus for collagen deposition is not exactly kown, but potential candidates are 
angiotensin II, aldosterone, growth factors like transforming growth factor and 
catecholamines 35• 
Changes in collagen content might be considered, again, as beneficial as well 
as maladaptive. On the one hand, collagen deposition probably can serve an adaptive 
role in the initial response to overload, where increased wall stiffness can reduce 
dilation and, as a consequence of the law of Laplace, lessen wall tension in the 
overloaded heart 57• On the other hand, it has been shown that even small increases 
in the amount of collagen can cause adverse effects on diastolic relaxation and result 
in stiffness 58• Indeed, deposition of collagen in the non-infarcted myocardium has 
been related to an increased myocardial stiffness and impaired diastolic heart 
function 59• 
Microcirculation 
As the heart progressively enlarges, coronary blood flow is limited by 
microvascular abnormalities and the high intramyocardial wall tension caused by the 
altered geometry of the now dilated and hypertrophied ventricle. Vascular adaptation 
of the vascular beds which are perfused by the remaining patent coronary arteries 
after myocardial infarction is required. The amount of contractile tissue which the 
patent coronary arteries feed has increased due to compensatory hypertrophy, and 
this myocardium has to operate at increased wall stress 45• Therefore, a greater 
amount of nutrients and oxygen is needed by the spared part of the heart. Increased 
oxygen delivery to hypertrophied viable tissue can be achieved by increasing resting 
coronary blood flow through dilatation of resistance arteries 60• If peak oxygen 
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demand of the hypertrophied viable myocardium exceeds the supply by the fully 
dilated vascular bed, ischemic stress will threaten function and viability of myocytes 
61
• In addition to this potentially inadequate oxygen supply by the coronary arteries, 
oxygen availibility may also be hampered at a cellular level by increased pathway 
length for oxygen to diffuse from interstitial capillaries to mitochondria within the 
cardiomyocyte 41 • 
In the non-infarcted myocardium, a decrease of the total capillary density and 
capillary to myocyte ratio has been reported 30 days after coronary artery occlusion 
in the rat 62. In the majority of studies, a deficit in the microvascular network was 
shown after myocardial infarction. Early investigations demonstrated that the 
capillarity is decreased in the hypertrophied myocardium whereas intercapillary 
distance increased due to a rise in cardiomyocyte diameter 63 Similar findings have 
been obtained in many subsequent experimental studies, in which the capiliary 
supply to the surviving hypertrophic cells was decreased in the early and late phases 
after infarction, as expressed in morphometric parameters like capillary density, 
capillary luminal volume, capillary surface density and elevated diffusion distances 
64
'
65
. From these studies, it was concluded that capillary density in the hypertrophied 
non-infarcted part decreased by up to 22% such that diffusion distances for oxygen 
were increased by 16%. The response of the coronary vasculature within the 
surviving myocardium could generate a relative energy .starvation that, in turn, may 
lead to local ischemia and tissue damage 47 and may account for the impaired 
performance of infarcted hearts. 
In the remodeled myocardium, vessel density is the result of angiogenesis and 
myocyte hypertrophy. In the non-infarcted myocardium of rat infarcted hearts, 
capillary angiogenesis is inadequate in maintaining normal tissue capillarization. 
Decreased capillary density is especially pronounced in the non-infarcted tissue near 
the infarct region 66• Small studies using autopsy material from human myocardium 
suggest that both capillary and arteriolar density are maintained 67, and even tend to 
be increased in infarction induced hypertrophy. This may suggest that angiogenesis 
in the vascular beds of the hypertrophied myocardium must have occurred. However, 
it remains unclear if besides infarction induced remodeling, additional ischemia due 
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to coronary artery atherosclerosis of the arteries supplying non-infarcted tissue 
increases the angiogenic response. 
Biochemical alterations 
Although reactive hypertrophy after myocardial infarction has the potential to 
restore the amount of contractile myocardium, the increased volume per cell is 
parallelled by a number of biochemical alterations in the myocytes that may be 
involved in the ultimate hemodynamic deterioration towards cardiac failure. 1) Mean 
oxygen diffusion distance is increased due to reduced cardiomyocyte surface to 
intercellular volume ratio, which is further aggravated by interstitial tissue volume 
and decreased capillary density 45•68 . This seems to be most pronounced in the area 
bordering the infarct zone. Cellular hypoxia may be detrimental, by limiting ATP 
production by mitochondrial oxidative phosphorylation in already functionally stressed 
myocytes. In addition, cellular hypoxia might trigger apoptosis, which would further 
reduce the numer of viable myocytes 69 • Cellular loss would then demand further 
hypertrophy of remaining myocytes, resulting in a vicious circle of events leading to 
heart failure. 2) Imbalance between ATP generating and ATP consuming processes is 
indicated by a decrease in ratio of mitochondria to myofibril number. Indeed, in the 
non-infarcted hypertrophied myocardium, energy reserve (intracellular levels of high-
energy phosphates) 70 and mitochondrial oxygen consumption rate are decreased 71 • 
Remodeled hearts display enhanced anaerobic metabolism, which was suggested by 
increased lactate hydrogenase activity and impaired creatine kinase activity in the 
residual contractile tissue bordering the infarct 72 • 3) In hypertrophied myocytes 
there seems to be an impaired calcium handling. Indeed, a significant reduction of 
ATP-dependent calcium uptake activity of sarcoplasmic reticulum membrane fractions 
has been observed in the non-infarcted myocardium bordering the infarcted area 73 • 
Furthermore, calcium sensitivity of myofibrils from hypertrophied myocardium has 
been reported to be reduced 73 . 4) In the non-infarcted myocardium of rats, a 
decreased ATPase activity of contractile apparatus has been reported resulting from 
a switch to a slower V3 myosin isoform 74• This chemical conversion can be regarded 
as an adaptive process that limits the excessive increase in oxygen consumption that 
might be expected with a significant increase in total muscle mass. 5) There seems 
22 
Chapter 1 Introduction 
to be an altered response to sympathetic stimulation in the non-infarcted 
myocardium due to a down-regulation of B-adrenoceptor number and reduced 
intracellular transmission of the signal 75•76• 
Thus, increased diffusion distance for oxygen may be the initiating stimulus for 
the aforementioned biochemical changes, since it can result from an increase of 
myocyte volume. Relative oxygen deficit of the myocyte and impaired oxidative 
phosphorylation capacity could be related to decreased potential of generating high-
energy phosphates and result in a number of changes affecting the contractile 
apparatus of the ~ardiomyocyte, such as lower ATPase activity of myofibrils and 
other energy-requiring processes. 
1.5. Pharmacological intervention on postinfarction remodeling 
In the 1970s, it was believed that vasodilator drugs worked primarily by 
reducing high systemic vascular resistance and thus by "unloading" the failing left 
ventricle. Undoubtedly, the picture is far more complex than this . It is clear that the 
concept of chronic afterload reduction of the failing heart with pure arteriolar 
vasodilator is now challenged and may no longer be tenable. This concept is now 
largely relegated to the treatment of acute or decompensated heart failure. The 
chronic use of therapies which increase ejection fraction by directy stimulating 
cardiac contractility (dobutamine, milrinone) or by decreasing impedance to left 
ventricular ejection through relaxation of peripheral blood vessels may relieve 
symptoms in the short term, but do not necessarily produce clinical benefits in the 
long term and may even increase mortality 3•77 • However, favourable experience with 
long-term vasodilator therapy in heart failure has been observed with the 
combination of isosorbide dinitrate and hydralazine in the V-HeFT II Trial 78• Initially 
combined because of their complementary dilating actions on periheral bloodvessels, 
recent evidence suggests that hydralazine and isosorbide dinitrate may act principally 
at a biochemical level rather than as conventional vasodilators. Pharmacological 
treatments may also improve ejecton fraction by affecting the process of cardiac 
remodeling. This approach utilized by neurohormonal blockade with ACE-inhibitors or 
B-adrenergic receptor blockers 3 has been shown to improve left ventricular 
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performance and patient survival when used on a chronic basis for the treatment of 
heart failure. In addition, diuretics with aldosterone blocking properties such as 
spironolactone have been shown to improve survival in patients with class III and N 
heart failure, adding further support for the neurohormonal hypothesis 79 • 
The above observations suggest that the most effective means of decreasing 
risk of hospitalization and death in patients with heart failure is to adress the primary 
mechanisms that contribute to disease progression rather than to stimulate the 
contractility of the failing left ventricle. The current working hypothesis in the 
treatment of heart failure is represented in Fig.2. 
1950s-1980s 
j Hemodynamic model 
Reduced contractility 
Pump dysfunction 
Treatment: 
-positive inotropic drugs to 
stimulate contractility 
-vasodilators to "unload" the heart 
-conventional drugs such as diuretics, digitalis 
1980s-2000 
Neurohormonal model I 
Progressive remodeling with 
impaired performance 
Treatment: prevention of 
progression with neuro-
hormone blockers 
-ACE-inhibtors 
-B-blockers 
-conventional drugs such as 
diuretics, digitalis 
Emerging therapies: 
-endothelin blockers 
-neutralendopeptidase inhib~ors 
-chimeric atrial peptides 
-cytokine inhibitors 
-matrix metalloproteinase inhibto 
Fig.2 Heart failure: a changing paradigm (Frands GS, 2001). 
1.5.1. Angiotensin converting enzyme (ACE)-inhibitors 
ACE-inhibtors have emerged as the cornerstone of heart failure therapy. The 
efficacy of ACE-inhibitors in attenuating left ventricular dilation after infarction was 
first demonstrated in the rat, and this effect on remodeling was associated with 
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improved survival. Observations on the effects of ACE-inhibition in infarcted rats 80•81 
have not only stressed the importance of cardiac remodeling in determing the clinical 
outcome, but also triggered numerous follow-up studies addressing the role of the 
renin-angiotensin-aldosterone system in the control of remodeling. The effects of 
captopril, furosemide, and placebo were studied in patients with asymptomatic left 
ventricular dysfunction 1 week after myocardial infarction 82• Captopril treatment 
resulted in a significant reduction in left ventricular end-systolic volume index, with 
increases in stroke volume index and ejection fraction, whereas treatment with 
furosemide and placebo was associated with significant increases in 
echocardiographic left ventricular volumes. 
The mechanism of improvement with ACE-inhibition is related in part to 
peripheral vasodilation, ventricular unloading, and the attenuation of ventricular 
dilation. There may be additional beneficial effects on the coronary circulation and 
intrinsic plasminogen-activating system 83 . Although coronary hemodynamic data 
have suggested a balanced effect of ACE-inhibitors on the coronary circulation, one 
study in patients with heart failure indicated that such treatment may worsen 
ischemia, because of the hypotension that compromises myocardial perfusion 84• 
Importantly, ACE-inhibition may have a direct effect on myocardial tissue 85 
preventing the inappropiate growth and hypertrophy stimulated by angiotensin II 
and other growth factors. Besides effects on hypertrophy, observations on increased 
interstitial collagen deposition and the inhibitory effect of ACE-inhibitor thereon 
resulted in the hypothesis that the renin-angiotensin-aldosterone system might be 
involved in the control of collagen synthesis in the cardiac interstitium 86• 
Previous experimental studies 81•87 have clearly demonstrated that early 
treatment with captopril in chronically infarcted rats resulted in prevention of 
hypertrophy which was associated with deterioration of in vivo haemodynamics. On 
the other hand in the rat myocardial infarction model, improved heart function was 
found with delayed captopril treatment 81• Furthermore, clinical trials evaluating early 
intervention with ACE-inhibitors in patients with acute myocardial infarction have not 
yielded uniform results. Whereas decreased mortality has been reported from some 
trials 7l!l8,89, others did not find improved survival 90' 93• 
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1.5.2. Angiotensin receptor blockers 
An alternative approach to inhibiting the actions of angiotensin II in patients 
with heart failure is the use of drugs that block the angiotensin II receptor. Whether 
angiotensin receptor blockers are equivalent or superior to ACE-inhibitors is still 
unclear, but several clinical trials are now underway. Several angiotensin II receptor 
antagonists have been approved for the treatment of hypertension (losartan, 
valsartan, irbesartan, candasartan and eprosartan), but none has been approved for 
use in heart failure. The actions of angiotensin II depend upon the presence of 
relevant angiotensin receptors. Angiotensin II receptors in the heart consist of at 
least two major subtypes 94 and have been characterized by using potent, highly 
selective antagonists of the angiotensin type 1 and 2 receptor (ATrR and AT rR). In 
the non-infarcted myocardium an increase in AT1-R number and AT1-R mRNA have 
been reported as well as an upregulation of AT2-R and AT ,-R mRNA in whole 
ventricular tissue 95•96. Activation of the AT1-R lead to the majority of known functions 
of the renin-angiotensin-aldosterone system, like vasoconstriction, renal salt and 
water retention, the drinking response, inotropy, chronotropy, and cell growth 97• The 
function of ATrR is less clear, but it has a possible role in growth and development, 
differentation and blood pressure regulation. Early AT1-R blockade in rats, 
significantly reduced interstitial collagen following myocardial infarction, without 
affecting cell proliferation. In contrast, early AT,-R blockade in rats abolished the 
increased cell proliferation 98, but completely lacked an effect on collagen deposition 
99
•
100
• More importantly, using the same experimental setup late but not early 
captopril treatment restored cardiac function following myocardial infarction. Starting 
the treatment with ACE-inhibitors, 7 or 14 days after infarction, improves cardiac 
function and the 1 year survival rate of infarcted rats B<l. AT,- but not AT1-R blockade 
had similar effects 100• Since this improvement coincided with effects on cell 
proliferation and not with effects on collagen, this implies that proliferative 
phenomena, rather than interstitial collagen, determine cardiac function following 
myocardial infarction. Moreover, since AT,-R blockade does not affect aldosterone, 
the role for angiotensin II seems to dominate. Intervention on the renin-angiotensin-
aldosterone system with AT,.antagonists also inhibits the hypertrophic response. 
26 
Chaoter 1 Introduction 
Although, again, afterload reduction may contribute to this effect, studies with AT-
receptor antagonists indicate a specific AT1-receptor mediated hypertrophic response 
in cardiomyocytes 97• The ELITE-study, which compared captopril with Josartan, 
showed a trend towards a reduction in mortality of AT1-antagonist treated patients 
101
• ELITE II, an ongoing trial designed to examine mortality, may further extend our 
understanding of the mechanisms underlying postinfarction remodeling, including the 
relative actions played by the kinins 102• 
1.5.3. 11-adrenergic receptor blockers 
Benefit of B-b\ockade therapy as a secondary preventive therapy for 
myocardial infarction has been demonstrated by data from large number of trials, 
which showed a significant mortality reduction 103•104• Clinical trials of several 
different B -blockers have shown that these drugs can produce hemodynamic and 
symptomatic improvement in chronic heart failure due to non-ischemic and ischemic 
cardiomyopathy 105•106• B -blockers have been shown to establish neuroendocrine, 
anti-arrythmic and anti-ischemic effects 107• Non-selective agents without intrinsic 
sympathomimetic activity appeared to have the maximal potential benefit 108• The 
mechanisms whereby B-adrenergic blockers improve left ventricular performance and 
reduce mortality are still not entirely clear. Early studies suggested that upregu\ation 
of reduced density of myocardial B-adrenergic receptors was a prime mechanism of 
action of B-blockers 109, but this has not been demonstrated with the newer B-
adrenergic blockers, such as carvedilo\ 110• A large multicentre heart failure trial has 
indicated that the addition of carvedilo\ to conventional therapy is associated with a 
decrease in mortality 107• 
Non-selective B -blockers such as carvedilol may attenuate remodeling, an 
effect associated with a significant reduction in subsequent adverse cardiac events 
111
• Whether B -blocking agents provide a benefit additional to ACE-inhibitor 
treatment in heart failure remains unknown. Although the rationale for combination 
treatment is strong when extrapolating from clinical trials with B -blockers after 
myocardial infarction, definitive data are Jacking. The mortality benefit from B-
blockade in heart failure patients is due to a reduction in both progressive heart 
27 
Chapter 1 Introduction 
failure and sudden death. Thus, in patients with heart failure, combination 
neurohormonal blockade may be optimal, although occasionally limited by 
hypotension. 
1.6. Outline of the thesis and hypothesis 
The response to acute myocardial infarction can be divided into different phases: 
1. Acute myocardial infarction induces a sudden decrease of cardiac output related 
to the size of infarcted area. 
2. CompeasatoN phase: A decreased cardiac output evokes activation of 
compensatory mechanisms, such as the sympathetic nervous system and renin-
angiotensin-aldosterone sytem. If these mechanisms cannot bring cardiac output 
back to acceptable levels, structural changes in the heart called hypertrophy and 
remodeling will follow. 
3. Compensated ohase: A relatively stabile phase with (partly) restored cardiac 
output but with decreased left ventricular function and ejection fraction has been 
established; a stage compensated heart failure, in which patients are often not 
recognized. 
4. Decompensation ohase: When symptoms of heart failure become overt, 
decompensation develops driven by the same mechanisms as in the previous 
phases, but with a very poor prognosis. 
Therapy during the different phases require different strategies. During phase 1 the 
objective of therapy is to limit infarct size by establishing reperfusion as quick as 
possible. Then, theoretically, phase 2 requires stimulation, phase 3 stabilization and 
support, and phase 4 inhibition of the same ongoing processes. Although still 
patients at stage 4 are clinically the most important ones, inclination towards earlier 
intervention is growing. The problem that may arise, however, is that earlier 
treatment, especially at stage 2 is aimed at the opposite direction as the later 
therapy. This problem is substantiated by the results of the 2 CONSENSUS trials, 
where delayed ACE-inhibitor ( enalapril) treatment had clearly beneficial effects 
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(CONSENSUS I), whereas similar treatment during early phases had detrimental 
effects (CONSENSUS 11)91 • Pharmacological research has mainly focused on stage 4 
when congestive heart failure is diagnosed and prognosis becomes very poor. Except 
for treatment with ACE-inhibitors, prognosis has not benefited substantially from all 
these research. During this stage, cardiac hypertrophy and remodeling have become 
a major target for therapy since they are associated with improved prognosis 112• 
When treatment should be started earlier, that is with ventricular dysfunction but 
before signs of heart failure, it implies interference with cardiac hypertrophy and 
remodeling, which during the early phase are regarded a pathophysiological response 
to compensate for the loss of contractile tissue. This indicates that treatment should 
therefore be selected carefully 81•91 • Thus, although the importance of treatment 
during the comoensatorv stage is now well acknowledged, a strategy is not 
established yet. 
HYPothesis 
We hypothesize that treatment during the earlv comoensatorv stage should be 
directed to oreservation of the total amount of contractile tissue. with optimal 
perfusion. 
The former implicates that reactive hypertrophy should not be inhibited, 
whereas perfusion can be enhanced by increased vascularization, or optimizing the 
use of existing vascularization by prolonged diastolic time or improved cardiac 
relaxation. In addition, interference with collagen should be minimized in order to 
preserve sufficient tensile strength and prevent left ventricular dilation. 
Experimental model 
Over the years, several animal models for heart failure have been developed 
mostly based upon conditions that lead to heart failure in man. In the present thesis, 
ligation of the left anterior descending coronary artery in rats, resulting in transmural 
infarction of the LV free wall, was used to study the structural and functional 
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consequences of a large myocadial infarction. The rat heart failure model has been 
shown to be a well established model of cardiac failure, which is associated with 
neurohormonal activation and remodeling of the cardiac structure 29•113. 
To test our hypothesis in this rat heart failure model, the following sets of 
experiments were performed: 
• In chapter 2, the effects of early treatment with a low-dose aspirin and 
methylprednisolone have been used to study the intereference with collagen 
deposition and its relation to left ventricular diastolic function. 
• In chapter 3, the effects of early sympatholytic treatment with moxonidine are 
evaluated on postinfarction induced sympathetic activation and its consequences 
for ventricular hypertrophy and collagen deposition. 
• In chapter 4; the effects of early moxonidine therapy on capillary density in 
relation to sensitivity to ischemia are investigated. 
• In chapter s, the effects of early treatment with vasopressin V1A and v, 
antagonists on in vivo hemodynamics and postinfarction remodeling have been 
studied. 
• In chapter q we compared the effects of early therapeutic intervention with 
aspirin, methylprednisolone, moxonidine and captopril on in vivo and intrinsic 
heart rate in relation to capillary growth in the non-infarcted myocardium. 
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ALTERED CARDIAC COLLAGEN AND ASSOCIATED CHANGES IN DIASTOUC 
FUNcnON OF INFARCTED RAT HEARTS 
Abstract 
Anti-inflammatory drugs have been shown to modulate collagen deposition during myocardial 
infarction (MI) induced remodeling. Chronic effects of methylprednisolone (5 mg/kg/day) and 
low-dose aspirin (25 mg/kg/day) on cardiac collagen and left ventricular diastolic function 
were studied in rat hearts, 21 days after MI. Left ventricular function was assessed at 
baseline and after ~-adrenergic stimulation with isoproterenol in isolated penfused hearts, 
using an intraventricular balloon. After diastolic arrest, left ventricular pressure-volume 
curves were obtained. Left ventricular dilation was defined as the corresponding left 
ventricular volume at 20 mmHg left ventricular diastolic pressure. In histological sectons, 
perivascular and interstitial collagen content were quantified morphometrically as the Sirius 
Red positive area in the non-infarcted interventricular septum. Impaired baseline left 
ventricular function of MI-hearts was improved by methylprednisolone but not by low-dose 
aspirin. Isoprotenerol significantly enhanced systolic function in all hearts, whereas it 
augmented the decrease in left ventricular diastolic pressure only in methylprednisolone 
treated MI-hearts. The rightward shift of the pressure-volume curve after MI was aggravated 
by methylprednisolone but not with low-dose aspirin treament. Low-dose aspirin reduced 
perivascular but not interstitial collagen whereas methylprednisolone decreased both 
perivascular and interstitial collagen. Our findings indicate that MI-induced collagen 
deposition in the spared myocardium can be affected by chronic therapy with low-dose 
aspirin or methylprednisolone. The effects on interstitial collagen seemed reflected in an 
altered left ventricular diastolic function. 
2.1. Introduction 
Large myocardial infarction (MI) is known to induce alterations in the collagen 
matrix of both the infarcted and non-infarcted region of the heart. In the course of 
post-MI remodeling, infarcted tissue is replaced by scar tissue with a high collagen 
content while in the non-infarcted tissue collagen content is increased as well 1•2• 
Deposition of collagen in the non-infarcted myocardium has been related to an 
increased myocardial stiffness and impaired diastolic heart function 3-s. In addition, 
the structural remodeling of the myocardial collagen matrix appears to contribute 
considerably to left ventricular (LV) dilation 6 and progression of LV dysfunction 7•8. 
In a previous study, we have shown in a rat MI-model that chronic 
administration of aspirin, in a non anti-inflammatory dose, prevented collagen 
accumulation in the spared myocardium in the first two weeks after MI 9 This 
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observation was associated with improved in vivo hemodynamics and absence of 
further increased LV cavity dimensions 10• On the other hand, high-dose aspirin, 
providing plasma levels associated with anti-inflammatory actions in humans was 
shown to be able to inhibit both the synthesis 11 and degradation of collagen in other 
rat tissues 12• Furthermore, anti-inflammatory therapy after MI may lead to a too 
large reduction of the tensile strength of the LV collagen network resulting in 
aggravation of chamber dilation, as has been reported with non-steroid anti-
inflammatory drugs (NSAIDs) as well as with steroids 1'"'5• Moreover, chronic 
treatment with steroids and NSAIDs have been shown to retard collagen deposition 
in scar tissue resulting in infarct thinning 16.17. Thus, although post-Ml cardiac fibrosis 
may contribute to impaired cardiac function it is not clear whether the infarcted heart 
would benefit from anti-fibrotic treatment. 
Therefore, in the present study the effects of chronical methylprednisolone and 
low-dose aspirin on interstitial and perivascular collagen deposition in 3 week old 
infarcted rat hearts were investigated, and related to effects on LV diastolic function. 
2.2. Methods 
2.2.1. Animals 
Male Wistar rats (Harlan, Zeist, The Netherlands) weighing 270-300 g were 
housed in groups of 2 or 3 on a 12-hour light-dark cycle with standard rat chow and 
water available ad libitum. The animals were subjected to sham-surgery or coronary 
artery ligation. All experiments were carried out after approval of the University 
ethics committee for the use of experimental animals and conform with the Guide for 
Care and Use of Laboratoy Animals. 
2.2.2. Myocardial infarction 
Under pentobarbital anesthesia (60 mg/kg i.p.), MI was induced by ligation of 
the left anterior descending coronary artery 18• Briefly, after intubation of the trachea 
an incision was made in the skin overlying the fourth intercostal space, with the 
overlying muscles separated and kept aside. The animals were put on positive 
pressure ventilation (frequency 65-70/min, tidal volume 3 ml) and the thoracic cavity 
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was opened by cutting the intercostal muscles. The heart was carefully pushed to the 
left and 6-0 silk suture was looped under the left descending coronary artery near 
the origin of the pulmonary artery. After returning the heart to its normal position, 
the suture was tied. Intercostal space was closed by pulling the ribs with 3-0 silk, the 
muscles were returned to their normal position and the skin incision was sutured. 
Sham-operated animals underwent the same surgical procedure, without the actual 
coronary artery ligation. Proper occlusion of the coronary artery resulted in an 
extensive transmural infarction comprising a major part of the LV free wall, with 
small variations in size 19• Infarct size was determined by planimetry at mid-
ventricular levels in transverse slices 20 as the percentage of LV circumference 9• 
2.2.3. Experimental protocols 
Infarcted rats were randomized to receive saline, aspirin or 
methylprednisolone. Aspirin (25 mgjkg; lysine-acetylsalicylic, Aspegic®, Lorex B.V., 
Maarssen, The Netherlands) was dissolved in saline and administered as daily i.p. 
injections of 1 mljkg, starting 2 days before surgery until the end of the experiment 
at 21 days after surgery. Methylprednisolone (5 mg/kg; methylprednisolone 
sodiumsuccinate, Methypresol®, Pharmachemie B.V., Haarlem, The Netherlands) 
was given as daily i.p. injections starting at the end of the acute inflammatory phase 
18
, from 7 days to 21 days after surgery. 
Untreated control rats were receiving once daily saline injections of 1mljkg i.p. 
from 2 days before until 21 days after surgery (control for asprin treatment) or from 
7 days to 21 days after surgery (control for methylprednisolone treatment). Because 
of no differences between controls, data were pooled. 
2.2.4. Left ventricular function 
At the end of the protocol, the hearts were rapidly excized under pentobarbital 
anesthesia and mounted for perfusion with an oxygenated Krebs-Henseleit buffer 
(composition in mM: NaCI 125, KCI 4.7, CaCJ, 1.35, NaHC03 20, NaH2P04 0.4, D-
glucose 10; pH=7.4; 37°C) at a constant pressure of 85 mmHg, using the 
langendorff technique. Hearts were paced at 350 beats/min (4V, 2ms). LV function 
was measured as isovolumetric developed pressure against a fiuid-filled latex balloon 
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placed in the left ventricle, and connected via a fiuid-filled catheter to a miniature 
low-volume displacement pressure transducer. The LV end-diastolic pressure was set 
to 10 mmHg by adjusting the balloon volume. Although this value for LV end-diastolic 
pressure is above the physiological values of sham-hearts, this was performed to be 
able to obtain any ~-agonist mediated decreases of the LV diastolic pressure. 
Coronary fiow was measured by a fiow probe (Transonic Systems, Ithaca, NY, USA) 
placed in the tubing just before the ostia of the coronary arteries. 
After a stabilization period of 15 min, variables were measured at baseline. In 
order to determine maximal LV performance during ~-agonist stimulation, responses 
to increasing doses of isoprotenerol (L -isoprotenerol hydrochloride, Sigma Chemicals, 
St. Louis, USA), ranging from 10'9 to 10" M, were determined. For each dose, 100 fll 
of isoprotenerol solution, dissolved in saline, was injected into the perfusing medium 
just before entering the coronary arteries. During the administration of isoprotenerol 
pacing was set to 450 beats/min in order to minimize arrythmias. After a re-
stabilization period, hearts were arrested in diastole with a 0.5 ml injection of a 1 M 
potassium chloride into the perfusing buffer. At 10 to 20 different LV ballon volumes, 
diastolic pressures in the range of 0 to 40 mmHg were obtained. For each heart, 
values were fitted into: pressure=c.e'"'ume+a. As a measure for LV dilation the 
corresponding volume at 20 mmHg LV pressure, V20, was calculated. 
2.2.5. Ventricular hypertrophy 
After completion of the functional measurements, hearts were removed from 
the Langendorff preparation and weighed after exclusion of the atria and large 
vessels. Ventricular hypertrophy was defined as the ratio of ventricular weight and 
body weight. 
2.2.6. Collagen content 
Briefiy, ventricles were cut into 4 transversal slices from apex to base and 
fixated with 3.6% phosphate-buffered formaldehyde for at least 24 h. After fixation, 
the slices were dehydrated and paraffin-embedded. Deparaffinized 5 flm thick 
sections were incubated for 5 min with 0.2% (wtfvol) aqueous phosphomolybdic acid 
and subsequently incubated for 45 min with 0.1% Sirius Red F3BA (C. I. 35780, 
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Polysciences Inc., Northampton, U.K.) in saturated aqueous picric acid, washed for 2 
min with 0.01 M HCI, dehydrated and mounted with Entellan (Merck, Darmstadt, 
Germany). 
Collagen content was quantified by morphometry. In the interventricular 
septum, remote from the infarcted area, interstitial collagen was determined as the 
Sirius Red positive area in 40 high power fields per heart 9•21• Areas that endosed 
signs of replacement fibrosis or bloodvessels, were excluded from analysis. 
Perivascular collagen was measured around 12 resistance arteries (lumen diameter 
<150 j.UT1) per heart, in the non-infarcted interventricular septum and viable left 
ventricular free wall. Perivascular collagen area was corrected for luminal area of the 
vessel 22• 
2.2.7. Data analysis 
All data are presented as means ± s.e.m. Data of infarcted rats were only 
included if the infarction comprized the major part of the LV free wall, since small 
infarctions are found to be hemodynamically fully compensated 23•24 • Estimation of 
infarct size by macroscopic appearance has proven to be a reliable method to 
recognize too small infarctions 4< 20%) 19• Differences between groups were 
analyzed (SigmaStatTM, Jande! Scientific, Erkrath, Germany) using one-way analysis 
of variance (ANOVA) followed by Bonferroni's post-hoc t-tests for multiple group 
comparisons 25 . Responses to increasing doses isoprotenerol in the different 
experimental groups were analyzed using two-way ANOVA for repeated 
measurements. Differences were considered statistically significant if P<0.05. 
2.3. Results 
2.3.1. Ventricular hypertrophy 
Three weeks after MI, infarct size as well as body and ventricular weight were 
measured in the different experimental groups (Table 1). Compensatory hypertrophy 
in MI -hearts, defined by the ventricular weight body weight ratio, was indicated by a 
14% rise of ventricular mass despite replacement of the major part of the LV free 
wall by lighter scar tissue. Treatment with low-dose aspirin did not affect cardiac 
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hypertrophy when compared to hearts from untreated MI-rats. Both body and 
ventricular weight of methylprednisolone treated MI-rats were significantly reduced 
when compared to untreated MI-rats. However, this resulted in an unchanged 
ventricular weight body weight ratio. No differences in infarct size were observed 
between the different groups. 
Table 1. Infarct size, body and ventricular weight measured in the different 
experimental groups 21 days after surgery 
Sham MI MI+MP MI+ASP 
n 10 12 7 6 
Infarct size(%) 43±2 41±3 44±3 
Body weight (g) 346±8 347±8 300±10 be 354±11 
Ventricular weight (mg) 1061±52 1211±54 b 1059±64 c 1261±61 b 
Ventricular weight/body 3.1±0.1 3.5±0.1 b 3.5±0.1 b 3.6±0.2 b 
weight (mg/g) 
a Data are presented as means± s.e.m. MI: myocardial infarction; MP: methylpred~nisolone (5 mgjkg/ 
day); ASP: aspirin (25 mg/kg/day). b: ?<0.05 vs Sham; ': P<O.OS vs MI. 
2.3.2. Cardiac collagen 
Photomicrographs of picrosirius red stained sections of interventricular septum 
containing interstitial and perivascular collagen for the different experimental groups 
are shown in Fig.l. Post-MI remodeling is associated with an increase in both 
interstitial and perivascular collagen. Whereas methylprednisolone treatment reduced 
interstitial as well as perivascular collagen deposition, low-dose aspirin only affected 
perivascular collagen. These observations were substantiated by the actual 
measurements as shown in Fig.2. 
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Interstitial collagen 
Perivascular collagen 
,--,.,..,...,_,.,.......,,..,..,c.,-
Fig. 1. Picrosirius red stained sections of interventricular septum showing interstitial 
(A/B/C/D) and perivascular collagen (E/F/G/H) 3 weeks after surgery. A/E: sham 
heart, B/F: untreated MI-heart, C/G: aspirin treated MI-heart, D/H: 
methylprednisolone treated MI-heart. The bar in photomicrograph A indicates 1001-Jm, 
and accounts for all micrographs. 
Methylprednisolone, however, reduced both interstitial and perivascular collagen 
when compared to untreated Ml-hearts. Moreover, methylprednisolone treatment did 
not significantly reduce scar collagen (34±4% in methylprednisolone treated Ml-
hearts versus 43±5% in untreated Ml-hearts). 
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2.3.3. Left ventricular function 
Fig. 2. Effects of treatment on interstitial (upper 
panel) and perivascular collagen {lower panel). 
Interstitial collagen is expressed as percentage of 
total tissue area while perivascular collagen as 
collagen to lumen ratio of resistance arteries. MI: 
myocardial infarction; ASP: low-dose aspirin (25 
mg/kg/day); MP: methylprednisolone (5 
mg/kg/day). *: P<O.OS vs Sham; #: P<O.OS vs 
MI. 
Variables of LV function as well as cardiac perfusion measured at baseline in 
isolated perfused rat hearts are summarized in Table 2. 
Table 2. Characterization of the experimental groups 
Sham Ml MI+MP MI+ASP 
n 10 12 7 6 
LVSP (mmHg) 89±6 58±6 b 78±7 67±6 
LVEDP (mmHg) 14±3 11±3 9±3 10±1 
+dP/d!max (mmHg/s) 3180±307 1731±197 b 2752±270' 2049±230 b 
-dP/d!max (mmHg/s) 2197±224 1246±177° 1714±155 1462±195 
Coronary fiow (ml/min) 10.9±1.0 10.3±1.0 7.7±0.9 12.2±0.7 
Cardiac perfusion (ml/min.g) 10.3±0.7 8.7±1.0 7.3±0.6 9.7±0.6 
a Baseline values obtained from isolated perfused rat hearts paced at 350 beats/min. Data are 
presented as means ± s.e.m. MI: myocardial infarction; MP: methylprednisolone (5 mg/kg/day); ASP: 
aspirin (25 mg/kg/day); LVSP: left ventricular systolic pressure; LVEDP: left ventricular end-diastolic 
pressure; +dP/dtmax and -dP/dtm<~x: maximum velocity of pressure rise and decline; b : P<O.OS vs 
Sham; ': P:50.05 vs MI. 
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In Fig.3, effects of increasing doses isoprotenerol on LV function are shown. LV 
systolic dysfunction in untreated MI-hearts was evidenced from a decreased baseline 
LV systolic pressure and peak velocity of LV contraction +dP/dtmax. 
Methylprednisolone treated MI-hearts showed an improved LV systolic function as 
manifested by an increased baseline +dP/dlinax, whereas maximal values obtained 
after isoprotenerol infusion were not different from hearts of untreated MI-rats. 
Cardiac perfusion at baseline was not changed in untreated MI-hearts when 
compared to sham-hearts. This was neither altered by treatment with aspirin or 
methylprednisolone. Cardiac perfusion in methylprednisolone treated MI-hearts was 
significantly lower at maximal stimulation with 10"5 M isoprotenerol (12.1±0.8 
mljmin.g) when compared to untreated MI-hearts (16.0±1.1 mljmin.g). In low-dose 
aspirin treated MI-hearts, LV function nor cardiac perfusion were significantly 
different from untreated MI-hearts at baseline and after isoprotenerol. 
Diastolic dysfunction in MI-hearts was substantiated by a significanW reduced 
baseline -<IP/dtmax which was not altered by low-dose aspirin or methylprednisolone. 
In methylprednisolone treated MI-hearts, isoprotenerol significantly augmented the 
decrease in LV end-diastolic pressure when compared to sham-hearts and untreated 
MI-hearts. The LV end-diastolic pressure in low-dose aspirin treated MI-hearts did 
not differ from untreated MI -hearts at any timepoint. 
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Fig. 3. Left ventricular functional variables measured in isolated perfused treated and 
untreated rat hearts after increasing concentrations of isoprotenerol. Effects of 
treatment on left ventricular systolic (LVSP) and end-diastolic pressure (LVEDP) are 
shown in the upper left and right panel while the effects on peak velocity of 
contraction (+dP/dtnaJ and relaxation {-dP/dtmax) are presented in the lower left and 
right panel. MI: myocardial infarction; ASP: low-dose aspirin (25 mg/kg/day); MP: 
methylprednisolone (5 mg/kgjday). *: curve significantly different from sham values 
P<O.OS; #: curve significantly different from MI values P<O.OS. 
23.4. Diastolic pressure-volume curves 
Post Ml-remodeling of the left ventricle resulted into a rightward shift of the 
diastolic pressure-volume (PV) curve (Fig.4.). Furthermore, the diastolic PV curves of 
Ml-hearts (n=13) were less steep compared to sham-hearts (n=25), as indicated by 
significantly reduced k-values of the exponential PV relationship: 76±8 (10-4) versus 
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118±7 (104 ) in hearts from sham-operated rats. Low-dose aspirin treated Ml-hearts 
(n=9) manifested no alterations in the diastolic PV curves when compared to 
untreated MI-hearts, whereas methylprednisolone (n=6) resulted in a further 
rightward shift of the diastolic PV relationship. LV dilation of MI-hearts, as indicated 
by an increased LV volume at 20 mmHg pressure (V20= 0.850±0.037 in sham and 
1.268±0.066 mljkg in non-treated infarcted hearts) was not affected by aspirin (V20= 
1.250±0.107 ml/kg) but significantly aggravated by methylprednisolone (V20= 
1.496±0.079 ml/kg). The steepness k of the diastolic PV relationship remained 
unchanged in both low-dose aspirin (58±8 (10 4 )) and methylprednisolone (96±13 
(104 )) treated Ml-hearts when compared to untreated Ml-hearts. 
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2.4. Discussion 
Fig. 4. Diastolic pressure-volume (PV) 
relationships obtained from treated and 
untreated rat hearts arrested in diastole. MI: 
myocardial infarction; ASP: low-dose aspirin 
(25 mg/kg/day); MP: methylprednisolone (5 
mg/kg/day). 
The present study was carried out to investigate whether treatment with aspirin 
or methylprednisolone would attenuate cardiac collagen and alter LV diastolic 
function in the 3 week old post-Ml remodeled rat heart. In a previous study, we have 
shown that a daily dose of 25 mgjkg/day (low-dose) aspirin inhibits thromboxane but 
not prostaglandin synthesis as the rat dose equivalent to chronic low-dose aspirin 
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treatment in patients 9• This low-dose of aspirin prevented interstitial and 
perivascular fibrosis in the spared myocardium, while leaving wound healing and 
reactive hypertrophy relatively unaffected during the first two weeks of post-MI 
remodeling. Besides a possible delay in the development, aspirin treatment showed 
no effect on in vitro LV dysfunction. However, 3 weeks of this low-dose aspirin 
treatment is associated with improved in vivo hemodynamics in conscious rats 10• 
The effects of low-dose aspirin were compared with the effects of 
methylprednisolone treament which has been shown to aggravate post-MI LV dilation 
15
• In order to avoid interference with the initial wound healing, methylprednisolone 
treatment was started 1 week after MI, at the end of the acute infiammatory phase 
18 
2.4.1. Collagen and diastolic pressure-volume relationship 
In the present study, LV dilation in MI-hearts was indicated by a rightward shift 
of the diastolic PV relationship and substantiated by an increased volume at 20 
mmHg. Post-MI remodeling induced accumulation of both interstitial and perivascular 
collagen in the non-infarcted interventricular septum. Although LV stiffness is 
strongly determined by collagen concentration and degree of fibrosis 3, the steepness 
of the diastolic PV relationship in MI-hearts decreased. This phenomenon may be 
explained by an effect of changed LV geometry on the steepness of the PV 
relationship. Indeed, early after MI the PV curve is shifted to the left with increased 
stiffness, while during the process of remodeling a rightward shift of the PV relation 
and decreased LV stiffness were observed 8 
Methylprednisolone was shown to retard the rate of MI healing, cause scar 
thinning and induce cavity dilation in MI-rats 15• To limit the effects on healing and 
scar formation treatment with methylprednisolone was started one week after MI. As 
was previously shown for aspirin, where at 2 weeks post-MI infarct collagen content 
was already normalized 9, methylprednisolone did not significantly reduce scar 
collagen content. In agreement with the studies of Mannisi, chronic treatment with 
methylprednisolone in MI-rats resulted in a further rightward shift of the diastolic PV 
curves, indicating aggravation of LV dilation whereas low-dose aspirin did not affect 
the diastolic PV relationship in MI-hearts. In previous studies, celeterious effects of 
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methylprednisolone treatment in terms of LV dilation have been explained by its 
interference with replacement fibrosis in the infarcted area 14•15 in addition to its 
effects on collagen in the non-infarcted myocardium. It could also be possible that 
methylprednisolone did aggravate the initial process of breakdown of pre-existing 
collagen fibers correlating with post-MI infarction 6• Aggravation of LV dilation in MI-
hearts treated with methylprednisolone is associated with both decreased interstitial 
and perivascular collagen. On the other hand, therapy with low-dose aspirin did not 
aggravate LV dilation and only reduced perivascular collagen. This observation 
suggests that a too strong prevention of interstitial collagen build-up in the non-
infarcted myocardium may promote LV dilation. In addition, prevention of collagen 
deposition by methylprednisolone or low-dose aspirin was not associated with 
alterations in diastolic stiffness. 
The changes in the diastolic PV relationship related to collagen may also be 
explained by an effect on the physical properties of the collagen network in MI-hearts 
rather than the absolute amount of collagen. In the present study, only total collagen 
content was measured. Changes in collagen type, degree of cross-linking, fiber 
organization and fiber thickness could also alter the mechanical properties of the 
myocardium as reported by previous investigators 26 • 
2.4.2. Left ventricular function 
LV systolic dysfunction 3 weeks after MI was evidenced from a decreased 
baseline LV systolic pressure and +dP/d4nax. Depressed LV function was not 
attributed to differences in cardiac perfusion, since this was not different between 
sham- and MI-hearts at any timepoint. As expected, isoprotenerol infusion 
augmented contractile function and relaxation in all experimental groups. 
Treatment with methylprednisolone improved baseline +dP/d4nax, but maximal 
values with isoprotenerol were not different from untreated MI-hearts. 
Glucocorticosteroids are known to be able to increase B-receptor number. A higher B-
receptor number 1 responsiveness at similar endogenous stimulation would explain a 
higher baseline contractility. Moreover, methylprednisolone was shown to accelerate 
the recovery of the decrease in B-adrenergic responsiveness caused by successive 
administrations isoprotenerol in rat hearts 27. Interesting in this regard is the 
52 
Chapter 2 Cardiac collagen and diastolic function 
significant lower perfusion of methylprednisolone treated MI-hearts, seen at the 
highest dose of isoprotenerol. Treatment with low-dose aspirin did not change LV 
function or myocardial perfusion compared to untreated Ml-hearts. 
LV diastolic dysfunction in MI-hearts was substantiated by a significantly 
reduced baseline -dP/dtmax which was not altered by low-dose aspirin or 
methylprednisolone. However, ~-stimulation with isoprotenerol induced a significant 
decrease in diastolic pressure in methylprednisolone, but not in low-dose aspirin or 
untreated MI-hearts. A possible explanation for the enhanced active relaxation 
observed in methylprednisolone treated hearts could be related to its effects on 
interstitial collagen network. Moreover, besides a reduction of total collagen amount, 
methylprednisolone has been reported to have a pronounced effect on the tensile 
strengh of the collagen network 28, which could have contributed to the altered active 
relaxation in the isolated MI-heart. This could also explain the aggravated LV dilation 
seen in methylprednisolone treated MI-hearts. Although generally regarded as 
detrimental, if the rightward shift of the PV-curve at similar slope would be 
responsible for the improved active relaxation with ~-stimulation, even some benefit 
may be considered. Alternatively, the above described interactions between 
methylprednisolone and the ~-adrenergic pathway could as well be involved in the 
improved diastolic function. Nevertheless, an enhanced relaxation normally would be 
associated with an increased perfusion. Therefore it remains difficult to explain why 
an augmented relaxation seen after maximal isoprotenerol was associated with a 
decreased cardiac perfusion in the methylprednisolone treated hearts. 
2.4.3. Conclusions 
The present findings indicate that pharmacological interference with the 
deposition of collagen in the non-infarcted myocardium may result in an altered LV 
diastolic function. Changes in interstitial rather than perivascular collagen seem to be 
important in the regulation of passive as well as active relaxation of the isolated 
heart. Whether improving LV relaxation could beneficially influence cardiac function 
remains to be elucidated. 
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CHRONIC ADMINISTRATION OF MOXONIDINE SUPPRESSES SYMPATIIETIC 
AcnYATION IN A RAT HEART FAILURE MODEL 
Abstract 
Excessive sympathetic activity contributes to cardiovascular abnonmal~ies which negatively 
affect the prognosis of heart failure. The present study evaluated the effects of moxonidine, 
an imidazoline I1 receptor agonist, on sympathetic activation and myocardial remodeling in a 
rat heart failure model. Rats were subjected to coronary artery ligation, and treated w~ 
moxonidine, 3 or 6 mg[kg/day, from 1 to 21 days after myocardial infarction. After 21 days, 
heart rate and blood pressure were measured in conscious, chronically instrumented rats. 
Plasma catecholamine levels were determined by ligh-performance liquid chromatography. 
Effects on post-myocardial infarction remodeling were evaluated from the ventricular weight 
body weight ratio and interstitial collagen deposition, measured morphometrically in the 
interventricular septum remote from the infarcted area. Moxonidine dose-dependently 
decreased myocardial infarction induced tachycardia but did not affect myocardial infarction 
reduced blood pressure. Plasma noradrenaline levels which were elevated after myocardial 
infarction, decreased below sham-values with 6 mg[kg/day moxonidine. Ventricular weight 
body weight ratio as well as interstitial collagen were significantly elevated in myocardial 
infarcted rats, and restored to sham values with 6 mg/kg/day moxonidine. These data 
suggest that moxonidine suppresses myocardial infarction induced sympathetic activation in 
a dose-dependent way as indicated by reduced heart rate and plasma noradrenaline levels. 
Furthenmore, post-myocardial infarction remodeling may be attenuated at a higher 
dose-range of moxonidine as shown by nonmalisation of ventricular weight body weight ratio 
and interstitial collagen. 
3.1. Introduction 
Myocardial infarction is one of the major causes of heart failure. Although 
activation of neurohormonal compensatory mechanisms following myocardial 
infarction initially may appear beneficial and adaptive to preserve blood pressure and 
cardiac output, excessive and prolonged sympathetic stimulation negatively affects 
the prognosis of heart failure 1•2. Adverse actions of high plasma catecholamine levels 
include trophic and toxic effects on cardiac myocytes 3, downregulation of 
B1-adrenoceptors, increased renin secretion and myocardial as well as vascular 
hypertrophy 4•5• 
Recently, imidazoline !1 receptors in the rostral ventrolateral medulla oblongata 
have been recognized as a new target for centrally-acting sympatholytic drugs such 
as moxonidine and rilmenidine 6•7. Moxonidine is used as a centrally active 
antihypertensive drug which reduces sympathetic outfiow and circulating levels of 
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catecholamines 8 While its antihypertensive action is well-characterized in 
experimental and clinical studies ''10, the potential efficacy of moxonidine in heart 
failure needs to be established. 
The present study was carried out to investigate the effects of chronic 
moxonidine therapy on myocardial infarction induced sympathetic activation and its 
consequences for cardiac remodeling in chronically, infarcted rats. Myocardial 
infarction in rats has proven to be a clinically relevant model for the consequences of 
myocardial infarction leading to heart failure 11'12• Twenty-one days after myocardial 
infarction, heart rate and blood pressure were measured in conscious, chronically 
instrumented rats. Plasma catecholamine levels were measured in collected arterial 
blood samples. Regarding the effects of moxonidine on post-myocardial infarction 
remodeling, cardiac hypertrophy as well as interstitial collagen in the interventricular 
septum were determined. 
3.2. Materials and methods 
3.2.1. Animals 
Male Wistar rats (Harlan, Zeist, The Netherlands) weighing 270-300 g were 
housed in groups of 2 or 3 on a 12 h light-dark cycle with standard rat chow and 
water available ad libitum. The experimental protocol was approved by the University 
ethics committee for the use of experimental animals and conformed with the Guide 
for Care and Use of Laboratoy Animals. 
3.2.2. Myocardial infarction 
Rats were subjected to sham surgery or coronary artery ligation. Under 
pentobarbital anesthesia (60 mg/kg i.p.), myocardial infarction was induced by 
ligation of the left anterior descending coronary artery 13• Briefly, after intubation of 
the trachea an incision was made in the skin overlying the fourth intercostal space, 
with the overlying muscles separated and kept aside. The animals were put on 
positive pressure ventilation (frequency 65-70/min, tidal volume 3 ml) and the 
thoracic cavity was opened by cutting the intercostal muscles. The heart was 
carefully pushed to the left and 5-0 silk suture was looped under the left descending 
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coronary artery near the origin of the pulmonary artery. After returning the heart to 
its normal position, the suture was tied. Intercostal space was closed by pulling the 
ribs with 3-0 silk, the muscles were returned to their normal position and the skin 
incision was sutured. Sham-operated animals underwent the same surgical 
procedure, without the actual coronary artery ligation. Proper occlusion of the 
coronary artery resulted in an extensive transmural infarction comprizing a major 
part of the left ventricular free wall, with small variations in size 14• 
3.2.3. Treatment 
Infarcted rats were randomized to receive subcutaneous implantation of 
osmotic minipumps (Aizet® 2001, AI.ZA Pharmaceuticals, Palo Alto, CA) filled with 
moxonidine. Minipumps were replaced each week under ether anesthesia. Sham-rats 
and non-treated myocardial infarcted rats underwent the same anesthesia and 
surgical procedure without the actual implantation of the minipumps. Moxonidine was 
dissolved in a 1 ml saline buffer with 20 ~I HAc and adjusted to pH=6-6.5 with NaOH 
to provide a final daily dose of 3 (low-dose) or 6 mgjkg (high-dose). Administration 
of moxonidine was started 24 h following myocardial infarction and continued until 
the end of the experiment at 21 days after surgery. 
3.2.4. Heart rate and mean arterial blood pressure 
At day 19 after coronary artery ligation, rats were re-anesthetized and a 
catheter (PE-10 heat-sealed to PE-50) was inserted in the abdominal aorta through 
the femoral artery to measure mean arterial blood pressure. The heparinized saline 
filled catheter was tunnelled under the skin, exteriorized at the back of the neck and 
closed with a metal plug. The animals were housed separately and allowed to 
recover for another 2 days before measurements. On the experimental day, the 
arterial catheter was connected to a pressure transducer (Viggo-spectramed, DT -XX, 
Bilthoven, The Netherlands) and signal was fed into a 68809-based microprocessor 
and compatible computer, sampling at 500 Hz. After one h stabilization, baseline 
values of mean arterial blood pressure and heart rate were obtained. Heart rate was 
measured as the frequency of the pulsatile pressure signal. 
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3.2.5. Catecholamines 
After the registration of heart rate and mean arterial blood pressure was 
completed, a 1 ml arterial blood sample was collected in a syringe containing 10 [.II 
EDTA (0.1 M) and put on ice. After centrifugation (4000 rpm for 1 min), plasma was 
collected in prechilled tubes filled with 1.2 mg glutathione. Plasma was stored at 
-80'C until assay. High-performance liquid chromatography was used to measure 
plasma concentrations of noradrenaline, adrenaline and dopamine, as described in 
detail by Boomsma et al. 15• 
3.2.6. Cardiac hypertrophy 
When the functional measurements were completed, rats were deeply 
anesthetized with pentobarbital. Then, the hearts were excised, blotted dry and 
weighed after removal of the atria and large vessels. cardiac hypertrophy was 
defined as the ratio of ventricular weight and body weight. 
3.2.7. Interstitial collagen 
Hearts were cut into 4 transversal slices from apex to base and fixated by 
perfusion with 3.6% phosphate-buffered formaldehyde for at least 24 h. After 
fixation, the slices were dehydrated and paraffin-embedded. Deparaffinized 5 [.tm 
thick sections were incubated for 5 min with 0.2% (wt!vol) aqueous 
phosphomolybdic acid and subsequently incubated for 45 min with 0.1% Sirius Red 
F3BA (C.I. 35780, Polysciences Inc., Northampton, U.K.) in saturated aqueous picric 
acid, washed for 2 min with 0.01 M HCI, dehydrated and mounted with Entellan 
(Merck, Darmstadt, Germany). In the interventricular septum, remote from the 
infarcted area, interstitial collagen was determined as the Sirius Red positive area in 
40 high power fields per heart 16•17• Areas that enclosed signs of replacement fibrosis 
or bloodvessels, were excluded from analysis. 
3.2.8. Data analysis 
All data are presented as means ± S.E.M. Data of infarcted rats were only 
included if the infarction comprized the major part of the left ventricular free wall, 
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since small infarctions are found to be hemodynamically fully compensated 12•18• 
Estimation of infarct size by macroscopic appearance has proven to be a reliable 
method to recognize too small infarctions (<20 %) 14• Differences between groups 
were analyzed (SigmaStatrM, Jande! Scientific, Erkrath, Germany) using one-way 
analysis of variance (ANOVA) followed by Bonferroni's post-hoc t-tests for multiple 
group comparisons 19• Differences were considered statistically significant if P<O.OS. 
3.3. Results 
Results comprise data from sham-rats (n=14), untreated (n=12), low- (n=7) 
and high-dose (n=7) moxonidine treated myocardial infarcted rats. Overall mortality 
following myocardial infarction was 38% and did not depend on the treatment used 
since death mainly occurred within the first 24 h after coronary artery ligation. No 
other than surgery related death were observed during the treatment period. 
3.3.1. Heart rate and mean arterial blood pressure 
As shown in Fig. 1, chronically infarcted rats showed a significantly increased 
heart rate (left panel) compared to sham-rats, which was associated with a 
decreased mean arterial blood pressure (right panel). Chronic administration of 
low-dose moxonidine resulted in a normalization of myocardial infarction induced 
tachycardia to sham-values whereas high-dose moxonidine decreased heart rate 
even significantly below sham-values. The observed decrease of mean arterial blood 
pressure in myocardial infarcted rats remained unaffected by moxonidine treatment. 
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Fig. 1. Heart rate (left pane~ and mean arterial pressure (right pane~ measured in conscious rats 
with chronic MI. HR: heart rate; MAP: mean arterial pressure; MI: myocardial infarction; 
MOXL: low-dose moxonidine (3 mg/kg/day); MOXH: high-dose moxonidine (6 mg/kg/day). *: 
P<O.Ol vs Sham; #: P<O.Ol vs MI. 
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3.3.2. Catecholamines 
Plasma catecholamine levels in the different experimental groups are shown in 
Fig. 2. Plasma noradrenaline levels were significantly elevated in untreated 
myocardial infarcted rats when compared to sham-rats. High-dose moxonidine 
reduced noradrenaline levels to about 50% the values of sham-rats. Plasma 
adrenaline and dopamine levels were not different between the experimental groups. 
c:::JSham lllllillll M [[]]] MI+MOX, ~ MI+MOXH 
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3.3.3. Cardiac hypertrophy 
Fig. 2. Plasma concentrations 
of catecholamines measured 
in arterial blood samples 
obtained from resting, 
conscious rats. MI: myocardial 
infarction; MOXL: low~dose 
moxonidine (3 mg/kg/day); 
MOXH: high-dose moxonidine 
(6 mg/kg/day). *: P<O.Ol VS 
Sham; #: P<O.Ol vs MI. 
Body weight before surgery as well as ventricular weight and body weight after 
21 days for the different experimental groups are summarized in Table 1. Although 
started at similar body weight, sham-rats gained more weight (37±7 g) as compared 
to myocardial infarcted rats (23±9 g). Low-dose moxonidine did not affect this 
(21±9 g) but rats treated with high-dose moxonidine did not gain weight during the 
experimental period (1±6 g). Although not accounting for all high-dose moxonidine 
treated infarcted rats, overall appearance of rats treated with high-dose moxonidine 
was less healthy as judged from their general behaviour and condition of the fur'0•21 • 
Untreated myocardial infarcted hearts weighed significantly more than 
sham-operated control hearts despite replacement of the major part of the left 
ventricular free wall by lighter scar tissue. 
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Table 1. Body weight and ventricular weight of rats in the different experimental 
groups 
Sham MI Ml+MOXc Ml+MOl<H 
n 14 12 7 7 
Body weight at day 0 (g) 296±5 301±4 279±6 297±5 
Body weight at day 21 (g) 333±7 320±10 301±5 299±9' 
Ventricular weight at day 21 (mg) 1174±37 1543±75' 1410±104 1076±24 b 
Data are presented as means ± s.e.m. MI: myocardial infarction; MOXL: low-dose moxonidine (3 mg 
/kg/day); MOXH: high-dose moxonidine (6 mg/kg/day). a: P<O.Ol vs Sham; b:P<O.Ol vs MI. 
Ventricular weight body weight ratio was increased after myocardial infarction and 
significantly reduced to sham-values in myocardial infarcted rats treated with 
high-dose moxonidine (Fig. 3, upper panel). Low-dose moxonidine induced no 
changes in ventricular weight body weight ratio compared to untreated myocardial 
infarcted rats. 
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~ MI+MOXri Fig. 3. Effects of moxonidine on post-MI 
remodeling. Cardiac hypertrophy indicated 
as the heart weight body weight ratio 
(upper panel) and interstitial collagen 
expressed as percentage of total tissue 
area (lower panel), are presented for the 
different experimental groups. VW/BW: 
ventricular weight body weight ratio; MI: 
myocardial infarction; MDXL: low-dose 
moxonidlne (3 mg/kg/day); MOXH: high-
dose moxonidine (6 mg/kg/day). *: 
P<O.Ol vs Sham; #: P<O.Ol vs MI. 
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3.3.4. Interstitial collagen 
Photomicrographs of picrosirius red stained sections of interventricular septum 
containing interstitial collagen are shown in Fig.4. 
Fig. 4. Picrosirius red stained sections of interventricular septum showing interstitial collagen (see 
arrows) 3 weeks after surgery. A: sham heart, B: untreated MI~heart, C: low-dose moxonidine (3 
mg/kg/day) treated MI-heart, 0: high-dose moxonidine (6 mg/kg/day) treated MI-heart. The bar in 
photomicrograph A indicates lOO!Jm, and accounts for all micrographs. 
Myocardial infarction induced remodeling was associated with a significant increase in 
interstitial collagen content of the interventricular septum compared to sham-values. 
Whereas interstitial collagen in low-dose moxonidine treated myocardial infarcted 
hearts did not differ from untreated myocardial infarcted hearts, treatment with 
high-dose moxonidine significantly reduced interstitial collagen compared to the 
values of untreated myocardial infarcted hearts. 
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3.4. Discussion 
3.4.1. General 
In recent years, both experimental studies and clinical trials have provided 
insight into the potential of drugs, which directly or indirectly attenuate the activity of 
the sympathetic nervous system such as angiotensin-converting enzyme inhibitors 
22
•
23 and ~-adrenoceptor anatagonists 24•25 to prevent progression of heart failure. 
The development of newer sympatholytic drugs such as moxonidine may offer an 
interesting alternative to peripheral ~- and a-adrenoceptor blockade for the 
treatment of heart failure. Moxonidine has been introduced into clinical practice for 
the treatment of hypertension 26 and shows less adverse side effects compared to 
first-generation centrally-acting antihypertensive drugs such as clonidine 27• In the 
light of these observations, the effects of chronic moxonidine therapy on sympathetic 
activation and post-myocardial infarction remodeling were studied in a 
well-established rat heart failure model 11•12•28 
3.4.2. Sympathetic activation 
Chronically infarcted rats manifested signs of sympathetic activation, i.e. a 
significantly increased heart rate accompanied by significantly elevated plasma 
noradrenaline levels. Accordingly, an augmented sympathetic activity associated with 
hemodynamic signs of heart failure, i.e. a decreased blood pressure and cardiac 
output, has been reported in one of our previous studies with myocardial infarcted 
rats 29• The observed tachycardia in myocardial infarcted rats could be explained by 
enhanced sympathetic activity and elevated plasma noradrenaline levels, since heart 
rate in vivo is strongly regulated by both sympathetic nerve activity and 
catecholamine concentrations 30 • Interestingly, if these myocardial infarcted hearts 
were isolated and perfused, heart rate is still higher than in sham-operated rats, 
suggesting changes in intrinsic activation of the sinus node 29• 
In keeping with a central reduction in sympathetic tone, myocardial infarcted 
rats treated with moxonidine showed a dose-dependent decrease in heart rate and 
plasma noradrenaline levels. A similar reduction in heart rate and plasma 
noradrenaline concentrations was observed in patients with severe congestive heart 
failure, receiving moxonidine orally for 2 to 12 weeks 31• In the present study, 
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moxonidine therapy did not affect mean arterial blood pressure in myocardial 
infarcted rats. A blood pressure lowering effect of moxonidine was not likely to occur 
in normotensive rats. On the other hand, in spontaneously hypertensive rats 
long-term administration of moxonidine was shown to exhibit a dose-dependent and 
long-lasting reduction in blood pressure usually accompanied by a reduction in heart 
rate 6• This may be a chronic rather than an acute effect of moxonidine, since in 
acute experiments (data not shown) a reduced heart rate was associated with an 
increase in blood pressure mediated by vascular a2-adrenoceptors 32• 
From an energetic point of view, the lower heart rate induced by moxonidine 
would be beneficial to the failing heart. Infarcted hearts display a lower mechanical 
efficiency at rest, which is amplified by tachycardia, thereby negatively affecting the 
relation between myocardial oxygen demand and supply 33• A reduction in hearte rate 
is, independent of its origin, associated with increased capillary growth, which would 
greatly improve oxygenation of the heart 34• Moreover, a decreased heart rate may 
lead to longer diastolic filling phase of the heart and improve diastolic function in heart 
failure. Since cardiac output and stroke volume are significantly reduced in severe 
heart failure, the lower heart rate with moxonidine could only be beneficial if stroke 
volume would be correspondingly increased to maintain cardiac output. Accordingly, 
as shown by Motz eta/. (1998), a 10% decrease in heart rate was associated with a 
20% increase in stroke volume in heart failure patients treated with oral moxonidine 
for 3 months. 
3.4.3. Cardiac remodeling 
Cardiac remodeling after myocardial infarction is strongly determined by cardiac 
loading conditions and neuroendocrine activation 35. In the rat heart failure model, 
large myocardial infarction evokes alterations in shape and size of the injured left 
ventricle and compensatory hypertrophy of the non-infarcted myocardium "· In the 
present study, myocardial infarcted rats were characterized by an increased 
ventricular weight body weight ratio at 21 days after surgery. Since body weight was 
not changed in these rats, oompensatory cardiac hypertrophy is indicated by a rise of 
ventricular mass despite replacement of the major part of the left ventricular wall by 
lighter scar tissue. Myocardial infarcted rats treated with high-dose moxonidine had 
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not gained weight 21 days after myocardial infarction. One explanation could be a 
decreased tolerance of moxonidine at higher doses since the general aspect of these 
rats was less healthy than other myocardial infarcted rats. Another explanation could 
be a reduced food intake. This suggestion is supported by data from spontaneously 
hypertensive rats chronically treated with 8 mg/kg/day moxonidine which also 
manifested loss of body weight 6• 
In hypertensive patients 36 as well as rats 37, moxonidine was shown to be 
highly effective in reversing cardiac hypertrophy and protecting myocardial structure, 
an effect which coincided with decreased plasma noradrenaline and renin 
concentrations. In the present study, prevention of cardiac hypertrophy was seen in 
myocardial infarcted rats treated with high-dose moxonidine, whereas low-dose 
moxonidine had no effect on cardiac hypertrophy compared to untreated myocardial 
infarcted rats. The pronounced effect of high-dose moxonidine on cardiac 
hypertrophy is in accordance with a strong suppression of sympathetic activity i.e. 
lower heart rate and plasma noradrenaline levels when compared to the lower dose. 
Although regression of hypertrophy with angiotensin-converting enzyme 
inhibitors and ~-adrenoceptor antagonists 22•38•39 has been recognized to improve 
heart function and prognosis in heart failure patients 40 as well as in myocardial 
infarcted rats, prevention of early hypertrophy after myocardial infarction may be 
regarded as compensatory and should be interfered with care. Previous experimental 
studies 12•41 have clearly demonstrated that early treatment with the captopril in 
chronically infarcted rats resulted in prevention of hypertrophy which was associated 
with deterioration of in vivo hemodynamics. On the other hand in the rat myocardial 
infarction model, improved heart function was found with delayed captopril treatment 
12
• Furthermore, clinical trials evaluating early intervention with angiotensin 
converting enzyme inhibitors in patients with acute myocardial infarction have not 
yielded uniform results. Whereas decreased mortality has been reported from some 
trials 4,..4, others did not find improved survival 4548• Therefore, our results suggest 
that the high-dose moxonidine in the present study may be too high for an optimal 
chronic therapy . 
Another event associated with post-myocardial infarction remodeling is the 
accumulation of interstitial 49 and perivascular collagen 17•5° Collagen accumulation in 
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non-infarcted tissue has been shown to increase ventricular stiffness in myocardial 
infarcted rats 51 • In the present study, a significant accumulation of interstitial 
collagen in the non-infarcted area was observed in hearts from untreated myocardial 
infarcted rats. High-dose moxonidine, which prevented cardiac hypertrophy, restored 
interstitial collagen content to sham-values, whereas low-dose moxonidine did not 
alter collagen content nor hypertrophy compared to untreated myocardial infarcted 
rats. In spontaneously hypertensive rats, moxonidine has been reported to normalise 
myocardial fibrosis and capillarization to physiological levels 37• On the other hand, a 
too large reduction of tensile strength of the collagen network could result in 
aggravation of chamber dilation, as has been reported with non-steroidal 
antHnfiammatory drugs and steroids 52•53 • 
Based on the findings of the present study, we conclude that moxonidine (3 
mgjkg/day) effectively suppresses sympathetic activation after myocardial infarction 
without effects on cardiac hypertrophy and fibrosis. Moxonidine at 6 mg/kg/day, 
however, attenuated sympathetic activity even significantly below sham values, 
indicating the loss of a major hemodynamic regulatory system, which coincided with 
prevention of cardiac hypertrophy and fibrosis. 
3.4.4. Clinical implications 
Therapeutic management of heart failure should be focused on the reduction of 
sympathetic activation and protection of cardiac function. Research into moxonidine 
has contributed to the renewal of interest in centrally-acting sympatholytics and their 
possible benefit in the syndrome of heart failure. Preliminary clinical observations so 
far, suggest tihat the efficacy of moxonidine in the treatment of heart failure is 
comparable to currently used drugs such as angiotensin-converting enzyme inhibitors 
or B-adrenoceptor anatagonists. Chronic heart failure patients treated witih oral 
moxonidine during a 3 montih period, showed decreased plasma noradrenaline levels 
with an improved hemodynamic profile 31•54• Furthermore, the adverse side effects 
which have been reported witih earlier central sympatholytics, seem to be less 
severe. 
According to the clinical observations, the findings of the present study show 
that moxonidine therapy effectively suppresses myocardial infarction induced 
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sympathetic activation in conscious, chronically infarcted rats as indicated by reduced 
heart rate and plasma noradrenaline levels. Furthermore, post-myocardial infarction 
cardiac remodeling, which also is an important prognostic factor in heart failure, 
could also be attenuated by moxonidine. However, the dose of moxonidine in the 
mangement of heart failure needs to be chosen carefully. Therapy with a high-dose 
of moxonidine may lead to an unphysiologically low sympathetic tone and prevent 
compensatory hypertrophy, which may negatively affect prognosis of heart failure. 
Whether the beneficial effects of moxonidine will be associated with an improved 
clinical outcome in heart failure patients, needs to be further investigated. 
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REsTORED CAPIUARY DENSilY IN THE SPARED MYOCARDIUM OF INFARCTED 
RATS IMPROVES ISCHEMIC TOLERANCE 
Abstract 
Myocardial infarction (MI) induced hypertrophy is associated with a decreased capillary 
density, which may negatively affect ischemic tolerance of the spared myocardium. The 
present study investigated the effects of moxonidine, a centrally-acting sympatholytic, on left 
ventricular (LV) hypertrophy and capillary density in relation to sensitivity to ischemia in 
infarcted hearts. Infarcted rats were randomized to recieve 3 or 6 mg/kg/day moxonidine 
from 1 to 21 days after MI. LV hypertrophy after MI was indicated by increased ventricular to 
body weight ratio, and was significantly inhibited by moxonidine. Histological analysis 
revealed that MI-induced concentric hypertrophy of the spared myocardium, as indicated by 
almost double cross-sectional area of Gomori stained myocytes, was completely prevented 
by 6 mgjkg/day moxonidine. This effect was accompanied by a a restored number of Lectin 
stained capillaries per tissue area. However, capillary to myocyte ratio was similar in all 
groups. LV dysfunction after MI, measured in isolated perfused hearts, was confinmed by 
decreased LV systolic pressure and +(dP/dt)m,. and was not affected by moxonidine. Low 
fiow ischemia, induced by lowering perfusion pressure from 85 mmHg to 15 mmHg for 30 
min resulted in a further reduction of cardiac perfusion compared to sham-rats, which was 
normalized w~h 6 mgjkgjday moxonidine. Ischemic sensitivity in MI-hearts, as reflected by 
increased maximal coronary flow during reperfusion, was reduced with moxonidine. This was 
further supported by substantially lower purines and lactate concentrations in the coronary 
effluent during ischemia. These results indicate that moxonidine induced prevention of 
hypertrophy, may preserve capillary density without affecting capillary number, thereby 
improving ischemic tolerance of the spared myocardium. 
4.1. Introduction 
Myocardial infarction (MI) induces compensatory hypertrophy and remodeling 
of the spared myocardium 1• Inadequate structural adaptation of the vascular bed to 
the hypertrophy of the surrounding myocytes may play a role in the progression from 
left ventricular (LV) dysfunction into heart failure 2• Indeed, vascular growth is 
inadequate to maintain normal capi\lary density of hypertrophied myocardium as 
shown in infarcted rat hearts 3• Moreover, a lower capi\lary density as a consequence 
of myocyte hypertrophy may limit oxygen supply and lead to ischemia during periods 
of increased coronary flow demand 
Therapeutic strategies, which focus on the prevention of MI-induced 
hypertrophy, have been shown to improve cardiac perfusion in both experimental 
and clinical studies •·6• Chronic angiotensin-converting enzyme (ACE) inhibition was 
shown to reduce cardiac hypertrophy, and improve myocardial capi\lary density in 
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chronically infarcted rats 7• Similar findings were described in coronary ligated rats 
treated with the AT, receptor antagonist losartan 8• Furthermore, treatment with 
captopril was shown to induce regression of hypertrophy thereby restoring maximal 
cardiac perfusion and leading to a better preservation of aerobic ATP production 
during ischemia 9. Besides ACE-inhibitors or p-adrenoceptor antagonists, prevention 
of hypertrophy after Ml can also be achieved by treatment with centrally-acting 
sympatholytic drugs such as moxonidine lO,n 
Recently, we showed that moxonidine effectively suppressed Ml-induced 
sympathetic activation and prevented LV hypertrophy in 3 weeks old infarcted rat 
hearts 12. Moreover, this study showed that other aspects of cardiac remodeling, 
such as interstitial fibrosis, were prevented by moxonidine treatment as well. 
Accordingly, in hypertensive rats moxonidine was shown to improve coronary 
microcirculation, as a consequence of decreased hypertrophy and fibrosis 10. 
However, whether these effects are related to preservation of adequate oxygen 
supply in the infarcted hypertrophied heart, is still unkown. Therefore, the aim of the 
present study was to investigate whether the effects of moxonidine on myocardial 
hypertrophy and capillary density are associated with a decreased sensitivity to 
ischemia. 
4.2. Materials and Methods 
4.2.1. Animals 
Male Wistar rats (Harlan, Zeist, The Netherlands) weighing 270-300 g were 
housed in groups of 2 or 3 on a 12 h light-dark cycle with standard rat chow and 
water available ad libitum. The experimental protocol was approved by the University 
ethics committee for the use of experimental animals and conformed with the Guide 
for Care and Use of Laboratoy Animals. 
4.2.2. Myocardial infarction 
Rats were subjected to sham-surgery or coronary artery ligation. Under 
pentobarbital anesthesia (60 mg/kg i.p.), MI was induced by ligation of the left 
anterior descending coronary artery 13. Briefty, after intubation of the trachea an 
incision was made in the skin overlying the fourth intercostal space, with the 
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overlying muscles separated and kept aside. The animals were put on positive 
pressure ventilation (frecuency 65-70/ min, tidal volume 3 ml) and the thoracic cavity 
was opened by cutting the intercostal muscles. The heart was carefully pushed to the 
left and &0 silk suture was looped under the left descending coronary artery near 
the origin of the pulmonary artery. After returning the heart to its normal position, 
the suture was tied. Intercostal space was closed by pulling the ribs with 3-0 silk, the 
muscles were returned to their normal position and the skin incision was sutured. 
Sham-operated animals underwent the same surgical procedure, without the actual 
coronary artery ligation. Proper occlusion of the coronary artery resulted in an 
extensive transmural infarction comprising a major part of the LV free wall, with 
small variations in size 9. Infarct size was determined by planimetry at mid-ventricular 
levels in transverse slices as the percentage of LV circumference. 
4.2.3. Moxonidine treatment 
Moxonidine was a generous gift from Solvay Pharma (Hannover, Germany). 
Infarcted rats were randomized for treatment with moxonidine at two different 
doses. For that, moxonidine was dissolved in saline (pH= &6.5) to provide a final 
daily dose of 3 (low-dose) or 6 mg/kg (high-dose) using subcutaneously implanted 
osmotic minipumps (Aizet® 2001, AL2A Pharmaceuticals, CA, USA). Administration of 
moxonidine was started 24 h following MI and continued until the end of the 
experiment at 21 days after surgery. Minipumps were replaced each week under 
ether anesthesia. Sham-rats and untreated MI-rats underwent the same anesthesia 
and surgical procedure without the actual implantation of the minipumps. 
4.2.4. Isolated heart perfusion 
At the end of the protocol, the hearts were rapidly excized under pentobarbital 
anesthesia and mounted for perfusion with an oxygenated Krebs-Henseleit buffer 
(composition in mM: NaCI 125, KCI 4.7, CaCI2 1.35, NaHC03 20, NaH2P04 0.4, D-
glucose 10; pH=7.4; 37°C) at a constant pressure of 85 mmHg, using the 
Langendorff technique. After 15 min of stabilization, hearts were paced at 350 
beats/min (4V, 2ms). LV function was measured as the isovolumetric developed 
pressure against a fluid-filled latex balloon placed in the left ventricle, connected to a 
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miniature low-volume displacement pressure transducer. LV end-diastolic pressure 
was set to 5 mmHg by adjusting the balloon volume. Coronary flow was measured by 
a flow probe (Transonic Systems, Ithaca, NY, USA) placed in the tubing just before 
the ostia of the coronary arteries. Cardiac perfusion was defined as the coronary flow 
corrected for ventricular weight. 
4.2.5. Ischemia and reperfusion 
To induce ischemia, perfusion pressure was lowered to 15 mmHg. At baseline 
and at the end of ischemia, coronary effluent was sampled on ice and stored at -80°C 
until assayed for purines and lactate concentrations. After 30 min of low-flow 
ischemia, perfusion pressure was reset to 85 mmHg. Reactive hyperemia was 
determined as the maximal coronary flow during reperfusion. When hemodynamics 
had stabilized again, at 25 min reperfusion, LV function was recorded and compared 
to baseline values before ischemia to indicate functional recovery. To examine 
whether maximal coronary flow during reperfusion indeed represent a functional 
response to the ischemic period rather than changes in absolute maximal coronary 
flow, the latter is obtained at the end of the experiments by bolus (0.1 ml) injection 
of a 10'2 M sodium nitroprusside solution (Dijkzigt University Hospital's pharmacy, 
Rotterdam, The Netherlands). 
4.2.6. Purines and lactate 
Release of purines into the coronary effluent was used to investigate loss of 
ATP catabolites from the heart 14•15. Cardiac loss of ATP catabolites during ischemia 
correlates well with myocardial ATP breakdown, as measured with f1P]- nuclear 
magnetic resonance 16• Concentration of purines was determined as described in 
detail by Smolenski et al. 17• Briefly, the ATP catabolites uric acid, adenosine, inosine, 
xanthine and hypoxanthine were determined by high-performance liquid 
chromatography on a Q8-J.LBondapak column (Millipore Waters Co., Milford, Mass, 
USA). Coronary effluent (100J.LI) was injected directly into the system, eluted with a 
15% (vjv) solution of acetonitrile in 150mM potassium dihydrogen orthophosphate, 
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containing 150mM potassium chloride adjusted to pH 6.0 with potassium hydroxide. 
Peaks were monitored by absorption at 254 nm or 280 nm for uric acid. 
The release of lactate into the coronary effluent was used as an indicator of 
anaerobic glycolysis in the cardiomyocyte. Lactate concentration in coronary effluent 
was determined as described in detail by Marbach & Weil (reagents: Sigma 
Diagnostics, Deisenhofen, Germany). Briefiy, lactic acid was converted by lactate 
oxidase to pyruvate and H,o,. In the presence of the formed H,o, peroxidase 
catalysed the oxidative condensation of chromogen precursors to produce a coloured 
dye with an absorption maximum at 540 nm. Lactate concentration could be 
determined, being directly proportional to the increase of absorption at 540 nm. 
4.2.7. Ventricular hypertrophy 
After completion of the functional measurements, hearts were removed from 
the Langendorff preparation and weighed after exclusion of the atria and large 
vessels. Ventricular hypertrophy was defined as the ratio of ventricular weight to 
body weight. \entricles were cut into 4 transversal slices from apex to base and 
fixated with 3.6% phosphate-buffered formaldehyde for at least 24 h. After fixation, 
the slices were dehydrated and paraffin-embedded. Deparafflnized 5 ~m thick 
sections were stained with a Gomori's silver staining 18 in order to visualize individual 
myocytes of the viable LV wall. Concentric myocyte hypertrophy in the viable LV free 
wall, remote from the infarcted area, was measured as the cross-sectional area of 
transversally cut myocytes showing a nucleus. Myocyte density was calculated as the 
average number of myocytes per tissue area. 
4.2.8. Capillary density 
To visualize the capillaries in the myocardium, endothelial cells were stained 
with Lectin GSI (Sigma-Aldrich Chemie©, Zwijndrecht, The Netherlands), as 
previously described by Nelissen-Vrancken. Sections of 5 ~m thickness were 
deparafflnized and rehydrated, and endogenous peroxidase was inhibited by 
methanoi/H,o, (0.3%) for 15 minutes. The sections were incubated overnight with 
the biotinylated Lectin GSI (1:100) at room temperature. Then, in a second step, the 
signal was intensified with an ABC-complex containing peroxidase labeled biotins 
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(1:100) (Lab vision, CA, USA). Finally, the sections were incubated with a Ni-Co 
amplified DAB solution to which a stable peroxide substrate buffer was added 
(Pierce©, CA, USA). Endothelial cells of capillaries and larger vessels are visualized in 
the myocardium as a brown precipitate. A background staining was not used in order 
to avoid interference with the Lectin staining. The number of capillaries were counted 
in the same region of the viable LV free wall in which myocyte area was determined. 
Capillary density in the viable LV wall was calculated as the number of capillaries per 
tissue area. Capillary to myocyte ratio was calculated as capillary density divided by 
myocyte density. 
4.2.9. Data analysis 
All data are presented as means ± S.E.M. Data of infarcted rats were only 
included if the infarction com prized the major part of the LV free wall, since small 
infarctions ( <20%) are found to be hemodynamically fully compensated 5•19• 
Estimation of infarct size by macroscopic appearance has proven to be a reliable 
method to recognize too small infarctions ( <20 %) 9• Differences between groups 
were analyzed (SigmaStat"', Jandel Scientific, Erkrath, Germany) using one-way 
analysis of variance (ANOVA) followed by Dunnett's and Bonferroni's post-hoc t-tests 
for multiple group comparisons 20 • A non-parametric data analysis (ANOVA on Ranks) 
was performed to analyze differences in purines and lactate levels. Differences were 
considered statistically significant if P<O.OS. 
4.3. Results 
Overall mortality following Ml was 38 % and did not depend on the treatment, 
since death mainly occurred within the first 24 h after coronary artery ligation. No 
other than surgery related death was observed during the treatment period with 
moxonidine. Results comprize data from sham-rats (n;14), untreated (n;12), low-
(n;7) and high-dose (n;7) moxonidine treated Ml-rats. In tables and figures low-
and high-dose moxonidine will be abbreviated as mox,and moxH, respectively. 
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4.3.1. Cardiac remodeling 
Three weeks after MI, body and ventricular weight as well as infarct size were 
measured for the different experimental groups (Table 1). The infarct size between 
untreated and moxonidine treated MI-hearts remained unchanged. Body weight of 
high-dose moxonidine treated rats was lower when compared to sham-rats. 
Ventricular weight of untreated MI-rats was significantly higher than sham-operated 
control hearts despite replacement of the major part of the left ventricular free wall 
by lighter scar tissue. Treatment with high-dose moxonidine normalized ventricular 
weight to sham-values. 
Table 1. Infarct size, body and ventricular weight measured in the experimental 
groups 21 days after surgery. 
n = 7-14 SHAM MI MI+mox, MI+moxH 
Infarct size(%) 45 ± 3 47± 5 44±3 
Body weight (g) 333 ±7 320 ± 10 301 ± 5 299 ± 9' 
Ventricular weight (mg) 1174 ± 37 1543 ±75' 1408 ± 104 1076 ± 24 b 
Data are presented as means±S.E.M. MI: myocardial infarction; moXL: low-dose moxonidine (3 
mg/kg/day); moXH: high-dose moxonidine (6 mg/kg/day); 'P<D.OS vs. SHAM;' P<O.OS vs.Ml. 
Moreover, ventricular weight to body weight ratio, which increased after MI, was 
significantly reduced to sham-values in high-dose moxonidine treated MI-rats (Figure 
2, lower pane[). 
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Photomicrographs of Gomori stained sections in the LV viable wall are shown in 
Figure 1. Ml-induced hypertrophy, which was microscopically confirmed by an 
increased myocyte area and decreased myocyte density, was dose-dependently 
restored to sham-values with moxonidine. 
Fig. 1. Gomori stained sections of LV viable wall obtained from the different experimental 
groups, showing individual myocytes. The bar in left upper photomicrograph indicates 
100 1-Jm, and accounts for all micrographs. 
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These observations were substantiated by the actual measurements in Figure 2 
(upper and middle pane{). 
Fig. 2. 
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Myocyte area (upper panel), myocyte density (middle panel) and ventricular weight to 
body weight ratio (lower panel) are presented for the different experimental groups. 
MI: myocardial infarction; moXt.: low-dose moxonidine (3 mg/kg/day); moXH: high-
dose moxonidine (6 mgfkg/day). *: P<O.OS vs Sham;#: P<O.OS vs MI. 
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Photomicrographs of Lectin stained sections in the LV viable wall showing capillaries 
are represented in Figure 3. The decreased capillary density observed in 
hypertrophied Ml-hearts, could be restored to sham-values with high-dose 
c:J SHAM E;SS] Ml+moxl 
- Ml ~ Ml+moXH 
5000 Capillary density 
4000 
2 
§ 2000 
c 
1000 
moxonidine. 
Fig. 3. Lectin stained 
sections of LV viable 
wall obtained from the 
different experimental 
groups, showing 
individual capillaries. 
These observations were substantiated 
by the actual measurements in Figure 
4. 
Fig. 4. Capil!ary density measured in untreated 
as well as moxonidine treated MI-hearts. MI: 
myocardial infarction; moXt.: low-dose 
moxonidine (3 mg/kg/day); moxH: high-dose 
moxonidine (6 mg/kg/day). *: P<O.OS vs Sham; 
#: P<O.OS vs MI. 
84 
Chapter 4 capillary density and ischemic tolerance 
The changes in capillary density could not be attributed to a change in actual 
capillary number, since capillary to myocyte ratio was similar in all groups 
(Sham:1.60±0.08; MI:1.70±0.20; mox,:1.70±0.17; moxH: 1.83±0.20). 
4.3.2. In vitro LV function 
In vitro heart rate, LV systolic and diastolic pressure as well as coronary flow, 
measured at baseline, before and after pacing, are summarized in Table 2. At 
baseline, untreated Ml-hearts were characterized by decreased LV systolic pressure 
and tachycardia, which was not affected by moxonidine treatment. LV diastolic 
pressure and coronary flow remained unaffected between the different experimental 
groups. 
Table 2. In vitro functional parameters measured at baseline before and after 
pacing 
n = 7-14 SHAM MI Ml+mox, MI+moxH 
Heart rate (beats/min) 208 ± 12 256 ± 11' 281 ± 18' 239 ± 17 
paced 354 ± 1 353 ± 2 352 ± 1 355 ± 1 
LV systolic pressure (mmHg) 77 ± 6 51± 7 a 66± 10 44± 5a 
paced 73 ± 6 45 ± 7 a 68 ± 11 48 ± 7a 
LV diastolic pressure (mmHg) 5±1 6±2 6±1 4±1 
paced 4±2 6±1 5±1 4±1 
Coronary flow (ml/min) 9.9 ± 0.9 9.6 ± 0.8 10.5 ± 1.8 10.2± 1.0 
paced 12.9 ± 1.1 10.1 ± 0.9 11.8 ± 2.0 10.9± 1.3 
Data are presented as means±S.E.M. MI: myocardial infarction; mo:<t_: low-dose moxonidine 
(3 mg/kgjday); moxH: high-dose moxonidine (6 mg/kg/day); 'P<0.05 vs. SHAM. 
LV dysfunction in paced untreated Ml-hearts was further confirmed by a significantly 
decreased peak velocity of contraction and relaxation at baseline as well as during 
ischemia and reperfusion (Figure 5, middle and lower panel). Moxonidine treatment 
did not affect peak velocity of contraction and relaxation. After 25 ·min reperfusion, 
LV function was fully recovered. 
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Fig. 5. Functional parameters measured in paced hearts at baseline, during ischemia and 
reperfusion. Upper panel: cardiac perfusion. Middle and lower panel: Peak velocity of 
contraction and relaxation. MI: myocardial infarction; moxL: low~dose moxonidine (3 
mg/kg/day); moXt;: high-dose moxonidine (6 mgjkg/day). *: P<O.OS vs Sham; #: 
P<O.OS vs MI. 
4.3.3. Ischemic sensitivity 
Whereas cardiac perfusion (coronary fiow corrected for ventricular weight) at 
baseline and during the reperfusion period was similar for all groups, ischemia 
depressed cardiac perfusion in all hearts but most pronounced in untreated Ml-hearts 
(Figure 5, upper panel). Furthermore, improved cardiac perfusion during ischemia 
was observed in high-dose moxonidine treated Ml-hearts. At reperfusion, coronary 
fiow increased to a maximum within 5 min and returned to baseline after 20 min. 
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Reactive hyperemia, as refiected by maximal coronary fiow during reperfusion, was 
significantly increased in Ml-hearts and decreased with moxonidine treatment (Figure 
6, left pane(). Maximal absolute values for coronary fiow, which were obtained after a 
bolus injection with sodium nitroprusside, were similar in all groups (Figure 6, right 
pane(). 
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Fig. 6. Maximal coronary flow during reperfusion and after bolus injection of sodium nitroprusside 
in sham-, and untreated as well as moxonidine treated MI-hearts. MI: myocardial infarction; 
moXJ,.: low-dose moxonidine (3 mg/kg/day); moxH: high-dose moxonidine (6 mg/kg/day). 
*: P<0.05 vs Sham; #: P<0.05 vs MI. 
Baseline values for purines and lactate concentrations were not different for 
the experimental groups. Low-fiow ischemia, which resulted in an approximately 
90% decrease of coronary fiow when compared to baseline (Ischemic flow: 
Sham:l.l±O.l; Ml:l.l±O.l; mox,:1.4±0.2; moxH:l.S±O.l ml/min), was associated 
with on average 14 times higher purines and 20 times higher lactate concentrations 
in the coronary effluent. The values of purines and lactate concentrations measured 
in the coronary effluent at the end of ischemia are shown in Figure 7. No differences 
for ischemic purines and lactate concentrations were observed between sham-hearts 
and untreated MI-hearts. In accordance with the observed decrease in reactive 
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hyperemia, high-dose moxonidine treated MI-hearts were characterized by 
substantially lower ischemic purines (Figure 7, left pane[) and lactate (Figure 7, right 
pane[) concentrations. 
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Concentration of purines (left panel) and lactate (right panel) in the coronary 
effluent measured at the end of ischemia. MI: myocardial infarction; moxL: 
low-dose moxonidine (3 mg/kg/day); moXt-t: high-dose moxonidine (6 mg/kg/day). 
4.4. Discussion 
4.4.1. Cardiac remodeling 
Post-MI remodeling is associated with alterations in shape and size of the 
injured left ventricle and compensatory hypertrophy of the non-infarcted myocardium 
3
•". In the present study, ventricular hypertrophy in MI-hearts was macroscopically 
shown by an increased ventricular weight to body weight ratio. Since body weight 
was not changed in Ml-rats, compensatory hypertrophy is indicated by a rise of 
ventricular mass despite replacement of the major part of the LV free wall by lighter 
scar tissue 12. Concentric rather than eccentric hypertrophy has been shown to be 
related with increased ischemic sensitivity 5• Furthermore, in a previous study we 
have shown that a decreased maximal myocardial perfusion is limited to the area 
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with the most pronounced cardiomyocyte hypertrophy, the spared part of the LV free 
wall 21 • In this area, concentric hypertrophy following MI was microscopically 
confirmed by an almost double myocyte cross-sectional area and decreased myocyte 
density. Whereas, in the present study, cardiac perfusion at baseline and during the 
reperfusion period was similar for all groups, ischemia depressed cardiac perfusion in 
all hearts but most pronounced in untreated MI-hearts. Furthermore, improved 
cardiac perfusion during ischemia was observed in high-dose moxonidine treated MI-
hearts. The impaired ischemic cardiac perfusion in untreated MI-hearts may be 
explained by a disproportional degree of hypertrophy relative to vascular adaptation. 
Improved cardiac perfusion observed with high-dose moxonidine is mainly due to a 
lower ventricular weight, since absolute coronary fiow was not changed. Indeed, 
complete prevention of ventricular hypertrophy was only seen with high-dose 
moxonidine, which restored myocyte area and ventricular weight to body weight 
ratio. These findings correspond with other clinical and experimental studies, in 
which moxonidine was shown to be highly effective in reversing cardiac hypertrophy 
12 and protecting myocardial structure 10•11• 
In hypertensive rats, cardiac hypertrophy has been found to be associated 
with an inadequate compensation of the capillary bed brought about by a relative 
decrease in capillary numerical density with no change in capillary size 22• Similarly in 
the present study, a significant reduction in capillary density was seen in the 
hypertrophied spared myocardium of MI-hearts, with unchanged capillary to myocyte 
ratio's. Indeed, an insufficient adaptation of the coronary vascular bed to the 
increase in cardiac muscle mass that has to be supplied, is consistent with the 
decreased capillary density found in the rat MI-model 1•23• Prevention of hypertrophy 
in moxonidine treated MI-hearts was associated with a normalization of capillary 
density. The effects of moxonidine on capillary density can be attributed to 
prevention of hypertrophy itself, rather than an angiogenic effect of moxonidine. This 
explanation was supported by the values of the capillary to myocyte ratio, which 
were similar for untreated as well as moxonidine treated MI-hearts. Improved 
coronary microcirculation attributed to decreased hypertrophy and collagen content 
was also observed in spontaneously hypertensive rats treated with moxonidine 10 
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The relationship between cardiac function and capillarization is not fully 
elucidated. In the present study, LV dysfunction of untreated MI-hearts was reflected 
by a decreased LV systolic pressure and increased in vitro heart rate. Furthermore, 
depressed LV function in MI-hearts was confirmed by a significantly decreased peak 
velocity of contraction and relaxation. 
Tachycardia in isolated perfused MI-hearts cannot be explained by an enhanced 
sympathetic tone, as was the case for the in vivo tachycardia observed in conscious 
MI-rats 12, but may rather be related to changes in intrinsic activation of the sinus 
node 24. Accordingly, whereas moxonidine was shown to normalize in vivo heart rate 
by suppression of sympathetic tone, it did not affect in vitro heart rate. Although 
prevention of hypertrophy with restored capillary density in high-dose moxonidine 
treated MI-hearts could be regarded as beneficial to the heart, this finding was not 
associated with an improved LV function. This may be explained by the fact that LV 
systolic pressure in moxonidine treated MI-hearts has to be developed from 
significantly less contractile tissue. In addition, LV function may be the net result of 
improved oxygenation to existing contractile elements and the amount of contractile 
tissue. 
4.4.2. Ischemic sensitivity 
MI induced cardiac hypertrophy 3 has been associated with enhanced ischemic 
vulnerability of the spared myocardium 25, which could be attributed to differences in 
cardiac perfusion, and increased oxygen diffusion distance with a relatively 
inadequate increase of capillary surface 3• Sensitivity to ischemia was evaluated from 
ATP breakdown products in the coronary effluent and maximal coronary flow during 
reperfusion. During ischemia, decreased ATP regeneration can result in the loss of 
ATP catabolites from the cell 14• This has been shown to be a sensitive marker for 
ischemia, since the concentration of the purines in the coronary effluent is lineary 
correlated with the degree of ATP breakdown and, hence, severity of ischemia 16•26 
In order to preserve intracellular ATP levels during ischemia, anaerobic glycolysis can 
be aCtivated. This would be associated with the release of lactate in the coronary 
effluent, which is used as an indicator of anaerobic glycolysis aCtivity of the 
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cardiomyocyte. Lactate production causes proton accumulation within the myocyte, 
which hampers cellular function. 
In the present study, 8 times lower coronary flow was associated with on 
average 14 times higher purines and 20 times higher lactate concentrations in the 
coronary effluent. This indicates actual ischemia-induced increased concentrations 
rather than flow-related increased concentrations. Whereas ischemic purines 
concentration from MI-hearts was not different from sham-hearts, improved 
tolerance to ischemia with high-dose moxonidine was supported by substantially 
lower purines concentrations. Since ventricular weight of high-dose moxonidine 
treated rats is lower compared to untreated MI-hearts, ischemic purines 
concentration may be corrected for ventricular weight and coronary flow; purine 
release. Nevertheless, this ischemic purine release was also lower in high-dose 
moxonidine treated MI-hearts (data not shown). 
A reduced loss of purines in high-dose moxonidine treated MI-hearts could be 
compensated for by a greater ATP production by anaerobic glycolysis. However, 
since lactate concentration in those hearts was lower as well, this does not seem 
feasible. Therefore, the explanation may rather lie in a lower ATP consumption in 
high-dose moxonidine treated MI-hearts. Indeed, moxonidine was shown to decrease 
myocardial oxygen consumption per unit weight of myocardium, thereby improving 
economics of cardiac function 27• Furthermore, the above findings are confirmed by 
the results of the maximal coronary flow during reperfusion. The heart is responding 
to transient ischemia with reactive vasodilation (reactive hyperemia) due to release 
of vasodilatory substances, such as nitric oxide 28 and adenosine 29 • Increased 
maximal coronary flow during reperfusion, therefore, is lineary correlated to an 
increased sensitivity to ischemia 30•31• Whereas an increased sensitivity to ischemia 
was observed in untreated MI-hearts, moxonidine decreased sensitivity to ischemia, 
as reflected by a reduced maximal coronary flow during reperfusion. On the other 
hand, increased ischemic sensitivity in MI-hearts was not correlated to higher 
purines or lactate values, which is probably due to a more efficient energetic 
adaptation of MI-hearts. Furthermore, the observation that maximal coronary flow 
after sodium nitroprusside was not different for the different experimental groups, 
implies that the changes in maximal coronary flow during reperfusion indeed reflect 
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responses to ischemia rather than indicate absolute coronary capacity. Improved 
ischemic tolerance with moxonidine is also supported by clinical studies, which 
showed restoration of coronary vasodilator reserve and improved maximal coronary 
blood ftow in patients with coronary artery disease 32. 
4.4.3. Conclusions 
Remodeling of the spared myocardium after MI may increase sensitivity to 
ischemia, and hence the risk of additional morbidity, and mortality. Reduced 
capillary density as a consequence of myocyte hypertrophy may limit oxygen supply 
and lead to ischemia during periods of increased coronary ftow demand. Therefore, 
reconstitution of cardiac mass with sufficient oxygen supply to the cells may be one 
of the therapeutic goals to improve the functional capacity of the ventricle in 
myocardial infarcted patients. The findings of the present study show that 
moxonidine therapy can prevent cardiac hypertrophy and restore capillary density in 
chronically, infarcted rat hearts. Furthermore, prevention of post-MI remodeling with 
moxonidine may contribute to a more aerobic metabolism during ischemia, thereby 
improving ischemic tolerance. Preliminary clinical observations so far, suggest that 
the efficacy of moxonidine in protecting myocardial structure is comparable to 
currently used drugs such as ACE-inhibitors 7, 33 or 6-adrenoceptor antagonists 34• 
Based on our present and previous findings, it should be emphasized that 
therapeutic efficacy of moxonidine highly depends on the used dosage. Whereas the 
lower dose of moxonidine only suppressed sympathetic activation, a dose which is 
only 2 times higher will also completely prevent the post-MI remodeling required for 
functional compensation. Indeed, although beneficial to the heart itself, complete 
prevention of hypertrophy after MI may deteriorate LV hemodynamics as shown in 
rats 5 and patients 35 treated with ACE-inhibitors. Accordingly, the promising effects 
of moxonidine on cardiac remodeling and microcirculation were not associated with 
improved LV function. 
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CHRONIC VASOPRESSIN VlA- BUT NOT V2 RECEPTOR ANTAGONISM PREVENTS 
HEART FAILURE IN CHRONICALLY INFARCTED RATS 
Abstract 
Evidence is increasing that therapeutic modulation of neurohormonal activation with 
vasopressin antagonists via VlA and V2 receptors may favourably affect prognosis of heart 
failure. This study was designed to compare in vivo hemodynamic effects of early treatment 
(1-21 days after infarction) with a VlA- (SR-49059; 0.3 mg/kg/day) and a v, (SR-1214636; 
0.5 mg/kg/day) receptor antagonist in infarcted (MI) rats, chronically instrumented for 
hemodynamic measurements. Left ventricular (LV) dysfunction in conscious MI-rats, which 
was evidenced by a significantly decreased cardiac output (MI: 70±3 vs Sham: 81±3 mlfmin) 
and stroke volume (MI: 190±10 vs Sham: 221±7 ~), was restored by the vasopressin Vv. 
(81±2 ml and 224±5~, respectively), but not v, antagonist. Improved cardiac output with the 
vasopressin VJA antagonist resulted from an increased stroke volume at a reduced MI-
induced tachycardia. In addition to the hemodynamic measurements, LV hypertrophy and 
capillary density were determined histologically measured as the cross-sectional area of 
Gomori stained myocytes and Lectin stained capillaries per tissue area, respectively. The 
observed LV concentric hypertrophy (MI: 525±38 vs Sham: 347±28 J.lrt1 2; P<0.05) and 
reduced capillary density (MI: 2068±162 vs Sham: 2800±250 number/mm'; P<0.05) in the 
spared myocardium of MI-rats, remained unaffected by the vasopressin VlA or V2 antagonist. 
ThUS1 chronic vasopressin VlA-, but not V2 receptor blockade prevents heart failure in 3 week 
old infarcted rats. Moreover, the improved cardiac function could not be attributed to 
changes in LV hypertrophy and/or capillary density. 
5.1. Introduction 
Neurohomonal activation after acute MI refers to increased activity of the 
sympathetic nervous system, renin-angiotensin system, atrial natriuretic peptide and 
arginine-vasopressin 1•2. Although initially compensatory in nature, prolonged 
neurohormonal activation after myocardial infarction (MI) has been shown to 
negatively affect prognosis of heart failure 3•4• Although angiotensin-converting 
enzyme inhibitors 5 and ~-adrenoceptors antagonists 6 have been shown to interfere 
with postinfarction remodeling resulting in improved prognosis of heart failure, 
current therapy is still not optimal. 
Another less investigated approach to achieve inhibition of prolonged 
neurohormonal activation could be obtained by blockade of the arginine vasopressin 
system. The antidiuretic hormone vasopressin plays a pivotal role in blood pressure 
control and salt and water homeostasis through its effects at the vasopressin V..A 
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receptor 7 to cause vasoconstriction and at the renal vasopressin V2 receptor to 
mediate antidiuresis 8• The recent development of vasopressin antagonists such as 
YM087, SR-49059 and OPC-31260, have allowed reevaluation of the precise role of 
vasopressin in the development of heart failure 9• However, currently there are only a 
limited number of studies examining the use of vasopressin antagonists as therapy 
for heart failure. Selective inhibition of the V1 and V2 receptor led to immediate 
improvement in hemodynamic parameters 10 and increased diuresis 8• 
Whereas previous studies have mainly focused on the acute and short-term 
hemodynamic and renal effects of V1A and V2 antagonism 11-13, the present study was 
designed to compare the in vivo hemodynamic effects of chronic treatment with a V1A 
and v, receptor antagonist in conscious infarcted rats. These rats have been shown 
to provide a well established postinfarction heart failure model 14• Furthermore, to 
investigate whether hemodynamic changes could be attributed to effects on 
postinfarction remodeling, LV hypertrophy and capillary density in the surviving 
myocardium were determined histologically using image analysis. 
5.2. Materials and methods 
5.2.1. Animals 
Male Wistar rats (Harlan, Zeist, The Netherlands) weighing 260-300 g were 
housed in groups of 2 or 3 on a 12 h light-dark cycle with standard rat chow and 
water available ad libitum. The experimental protocol was approved by the University 
ethics committee for the use of experimental animals and conformed with the Guide 
for Care and Use of Laboratoy Animals. 
5.2.2. Myocardial infarction 
Rats were subjected to sham surgery or coronary artery ligation. Under 
pentobarbital anesthesia (60 mg/kg i.p.), myocardial infarction was induced by 
ligation of the left anterior descending coronary artery 14• Briefly, after intubation of 
the trachea an incision was made in the skin overlying the fourth intercostal space, 
with the overlying muscles separated and kept aside. The animals were put on 
positive pressure ventilation (frequency 65-70/min, tidal volume 3 ml) and the 
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thoracic cavity was opened by cutting the intercostal muscles. The heart was 
carefully pushed to the left and 6-0 silk suture was looped under the left descending 
coronary artery near the origin of the pulmonary artery. After returning the heart to 
its normal position, the suture was tied. Intercostal space was closed by pulling the 
ribs with 3-0 silk, the muscles were returned to their normal position and the skin 
incision was sutured. Sham-operated animals underwent the same surgical 
procedure, without the actual coronary artery ligation. Proper occlusion of the 
coronary artery resulted in an extensive transmural infarction comprising a major 
part of the left ventricular free wall, with small variations in size 15• Infarct size was 
determined by planimetry at mid-ventricular levels in transverse slices 16 as the 
percentage of LV circumference 17. 
5.2.3. Treatments and doses 
Vasopressin antagonist treatment was administered from day 1 to 21 after MI. 
Therefore, rats were randomized to receive subcutaneous implantation of osmotic 
minipumps (Aizet® 2001, AL2A Pharmaceuticals, Palo Alto, CA) filled with the 
vasopressin v,. receptor antagonist SR-49059 or vasopressin V, receptor antagonist 
SR-1214636 (generous gifts from Sanofi, Montpellier, France). Minipumps were 
replaced each week under light ether anesthesia. Sham-rats and non-treated 
myocardial infarcted rats underwent the same anesthesia and surgical procedure 
without the actual implantation of the minipumps. The V1A receptor antagonist SR-
49059( (25) 1-[ (2R35)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-
3-hydroxy-2,3-dihydro-1H-indole-2-car-bonyl]-pyrrolidine-2-carboxamide) (Serra-deii-
Le Gal, 1994) and V, receptor antagonist SR-1214636 were dissolved in dimethyl 
sulfoxide at 3.75 mg/ml and 1.25 mg/ml, respectively, to provide a final daily dose of 
0.3 mg/kg/day and 0.5 mg/kg/day. In pilot experiments the used dose of the v,. 
receptor antagonist for 3 weeks, caused a rightward shift of the vasopressin 
pressure-response curve one log unit, while the used dose of the v, receptor 
antagonist chronically increased 24 h urine production by 20% (data not shown). 
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Fig. 1. cardiac output (upper panel), stroke volume (middle panel) and heart rate (lower 
panel) measurements obtained from sham, untreated infarcted and vasopressin 
antagonists treated infarcted rats. *: P<O.OS vs Sham; #: P<O.OS vs MI. 
5.3.3. Cardiac remodeling 
Representative photomicrographs of Gomori stained sections in the LV viable 
wall are shown in Fig.2 (Panel A). MI-induced LV hypertrophy at cellular level, which 
was confirmed by a significantly increased myocyte cross-sectional area, was not 
affected by vasopressin v,. or V2 antagonist treatment. 
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A 
Sham MI 
Fig. 2. Representative micrographs of Gomori as well as Lectin stained sections in the left 
ventricular viable wall of the different experimental groups, showing individual 
myocytes (Panel A) and, respectively, individual capillaries (small dark brown circles) 
(Panel B). The bar in left upper photomicrograph indicates 100 IJm, and accounts for 
a!! micrographs. MI: untreated infarcted rats; MI+VlA: vasopressin VJA antagonist 
treated infarcted rats; MI+V2: vasopressin V2 antagonist treated infarcted rats. 
These observations were substantiateo by the actual measurements as presented in 
Fig.3 (upper panel). Figure 2 (Panel 8) shows representative photomicrographs of 
Lectin staineo sections in the LV viable wall showing individual capillaries. Reduced 
capillary density, which was observed in MI-induced hypertrophied hearts, remained 
unaffected by treatment with vasopressin antagonsists. This was confirmed by the 
actual measurements in Rg.3 (lower panel). In addition, capillary to myocyte ratio 
was similar in all groups (Sham: 1.31±0.12; MI: 1.37±0.14; MI+V1A: 1.27±0.08; 
MI+V,: 1.41±0.19). 
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5.4. Discussion 
5.4.1. In vivo hemodynamics 
The important role of neurohormonal activation in the progression of heart 
failure and LV dysfunction is well established 22• That vasopressin may contribute 
importantly to this process, is supported by prior studies demonstrating elevated 
arginin vasopressin levels in acute as well as chronic heart failure 23-25• When 
antivasopressor V1-receptor antagonists became available for intravenous use in 
humans, it was shown to produce a hemodynamic improvement with transient 
decrease in systemic vascular resistance and increased cardiac output 26• Moreover, 
understanding of the functional significance of vasopressin in heart failure have also 
been achieved with V2-receptor antagonists, which were shown to improve diuresis 
and increase free water clearance in experimental models 27•28 as well as humans 29• 
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In contrast to previous studies, which mainly examined the acute effects of 
vasopressin receptor antagonism, the present results demonstrate that chronic 
treatment with the V1A receptor antagonist SR-49059, but not the V2 receptor 
antagonist SR-1214636, could improve in vivo hemodynamics in a postinfarction rat 
model of heart failure. Whereas LV dysfunction in untreated conscious MI-rats was 
reflected by a significantly decreased stroke volume and cardiac output, chronic VlA 
receptor blockade restored these functional parameters. Furthermore, whereas acute 
administration of V1A and V2 antagonists in MI-rats significan~y reduced mean arterial 
blood pressure and more than doubled urine production 13, chronic treatment did not 
alter cardiac loading conditions as reflected by mean arterial pressure, central venous 
pressure and total peripheral resistance. Thus, an improved stroke volume and 
cardiac output with the v,A antagonist, but not V2 antagonist, could not be attributed 
to changes in pre- or afterload. In addition, a lowered in vivo tachycardia as 
observed with the vasopressin V1A antagonist may be advantageous in terms of 
improving myocardial oxygen delivery by enhanced tissue perfusion through longer 
diastolic time 30 . The hemodynamic results of this study are fully supported by 
observations in a rat model of postinfarction heart failure in which short-term therapy 
with a combined VWV2 receptor antagonist resulted in a increased cardiac output 
however at substantial increased urine output 31• Hemodynamic improvement with 
this combined vwv2 receptor antagonist could, based on the findings of the present 
study, be mainly attributed to the effects of v,A antagonism. 
5.4.2. Cardiac remodeling 
Alterations in the cardiac structure may be responsible for improved cardiac 
function in vasopressin VlA antagonist treated MI-rats. Therefore, its effects on LV 
hypertrophy and capillary density were investigated. Postinfarction remodeling is 
associated with alterations in shape and size of the injured left ventricie and 
compensatory hypertrophy of the spared myocardium with reduced capillary density 
32
. Although ACE-inhibitors 33 and ~-blockers 34 are now extensively used to treat 
functional and structural consequences following large MI, little is known about the 
effects of vasopressin-antagonists on cardiac remodeling. 
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In the present study, LV hypertrophy associated with a lower capillary density 
was observed in the spared myocardium of untreated MI-rats, which was not 
affected by treatment with the vasopressin V1A or V2 antagonist. The lower capillary 
density directly results from LV hypertrophy since capillary to myocyte ratio remained 
unchanged. Hemodynamic improvement at a preserved hypertrophic response during 
early post-MI treatment supports our hypothesis that complete prevention of MI-
induced compensatory hypertrophy, as was observed with early ACE-inhibitor 
therapy, deteriorates rather than improves LV hemodynamics in MI-rats 18• Recent 
studies have demonstrated that in addition to other neurohormones, vasopressin 
increases the rate of protein synthesis in the myocardium, leading to myocyte 
hypertrophy, a direct effect mediated by the V1A receptor 35•36. However, in the 
present study antagonizing the V1A or V2 vasopressin receptors did not affect 
myocyte hypertrophy and, without a direct effect on capillary growth, capillary 
density remained reduced. A minor role of vasopressin compared to the renin-
angiotensin-system in promoting LV hypertrophy might be one explanation. From 
these results, we may assume that improved cardiac function observed with the 
vasopressin V1A antagonist is not due to changes in hypertrophic response and 
myocardial capillarity. 
5.4.3. Conclusions 
It is conceivable that in the setting of neurohormonal blockade with ACE-
inhibitors, ~-blockers, and aldosterone-antagonists, other neurohormones such as 
vasopressin begin to play a more prominent role in the subsequent progression of 
heart failure. Currently there are only a limited number of studies examining the use 
of vasopressin antagonists in human heart failure. In general, vasopressin 
antagonism has been shown to improve hemodynamics and diuresis in several 
models of heart failure. The results of the present study showed that chronic 
vasopressin v,A-, but not V2 receptor blockade prevented heart failure in chronically 
infarcted rats. Interestingly, in our hands this is the very first treatment administered 
during the first 3 weeks, that actually improved cardiac output. Previous work 
resulted at the most in a sustained depressed cardiac output, but at a lower heart 
rate and improved stroke volume 37• The observed improvement of cardiac function 
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in these rats could not be attributed to changes in LV hypertrophy and capillary 
density. However, in line with the observations with ACE-inhibitor therapy 18, effect of 
early treatment with vasopressin receptor antagonists may not predict effects of 
more delayed treatment. These aspects need further investigation. 
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CHAPTER6 
Lower intrinsic rather than actual 
in vivo heart rate contributes to 
capillary angiogenesis in infarcted 
rat hearts 
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lOWER INTRINSIC RATHER THAN ACTUAL IN VIVO HEART RAlE CONTRIBUTES 
TO CAPILLARY ANGIOGENESIS IN INFARClED RAT HEARTS 
Abstract 
Postinfarction remodeled hearts display a lower mechanical efficiency amplified by 
tachycardia. Furthermore, in these hearts a lower capillary density negatively affects 
myocardial oxygen supply. The present study investigated the relation between heart rate (in 
vivo and intnnsic) and capillary angiogenesis in the surviving myocardium of chronically 
infarcted (Ml) rats treated w~h aspirin (25mg/kg/day; i.p., n=6-12), methylprednisolone 
(5mg/kg/day; i.p.;n=7-12), moxonidine (6mg/kg/day; osmotic minipumps; n=7-14) and 
captopril (2g/l drinkwater; n=7-10). While actual in vivo heart rate was measured in 
conscious rats as the frequency of aortic pressure signal, intrinsic heart rate was measured 
from spontaneously beating isolated perfused hearts. Infarcted rats manifested a significant 
in vivo tachycardia (mean values; MI: 386±9 vs. Sham: 354±7 beats/min) as well as 
increased intrinsic heart rate (mean values; MI: 274±8 vs. Sham: 229±8 beats/min) when 
compared to sham-rats. Whereas aspirin, methylprednisolone and moxonidine significantly 
reduced infarction induced in vivo tachycardia, captopril further increased in vivo tachycardia. 
Increased intrinsic heart rate in infarcted hearts was reduced to sham-values with aspirin and 
methylprednisolone, but not with moxonidine and captopril. Concentric left ventricular 
hypertrophy, defined as cross-sectional area of transversally cut Gomori stained myocytes, 
was indicated by an almost double myocyte area (mean values; Ml: 586±45 vs. Sham: 
320±26 ~m'; P<0.05), and prevented by methylprednisolone, moxonidine and captopril 
(P<0.05), but not aspirin. capillary density, which was defined as the number of Lectin 
stained capillaries per tissue area, significan~y decreased in infarcted hearts (mean values; 
Ml: 1949±27 vs. Sham: 3363±26 number/mm') at maintained capillary to myocyte ratio, but 
was increased by all treatments (P<0.05). Moreover, treatment with aspirin and 
methylprednisolone, but not moxonidine and captopril, resu~ed in an even increased 
capillary to myocyte ratio when compared to untreated infarcted hearts (P<0.05). The 
present results show that prevention of left ventricular hypertrophy 'nonmalizes capillary 
density without affecting capillary number. Moreover, normalized intrinsiC rather than in vivo 
tachycardia is associated with actual capillary growth in chronically infarcted hearts. 
6.1. Introduction 
Large myocardial infarction (MI) is known to induce remodeling of the surviving 
myocardium, which includes compensatory hypertrophy of cardiomyocytes, interstitial 
fibrosis, and limited adaptation of the capillary microvasculature. Early investigations 
have reported a decreased capillary supply to the surviving hypertrophic myocytes in 
the early as well as late phases after MI 1. Normalization of the relation between 
cardiac muscle growth and capillarization is associated with improved function of 
non-infarcted myocardium, and may thus beneficially affect clinical outcome 2• 
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Vascularization in remodeled infarcted hearts can be improved by inhibition of 
reactive hypertrophy, as was shown for ACE-inhibtors 3• However, immediate and 
complete prevention of compensatory hypertrophy after MI with captopril was shown 
to have deleterious effects on cardiac function of infarcted rats 4 • Alternative 
strategies to stimulate capillary growth in the infarcted heart include the use of 
growth factors, such as vascular endothelial growth factor or basic fibroblast growth 
factor 5, and long-term reduction of heart rate 6• Bradycardia has been demonstrated 
to improve tissue perfusion by increasing diastolic time 7•8 and appears to induce 
capillary angiogenesis irrespective of the cause of heart rate reduction 6• 
A major consequence of MI is the activation of the sympathetic nervous system, 
leading to increased heart rate and plasma catecholamines levels 9•10• However, 
besides MI-induced in vivo tachycardia, in vitro or intrinsic heart rate of isolated 
perfused MI-hearts was also found to be increased 11•12• Chronic therapy with aspirin 
and moxonidine in the early compensatory phase after MI, reduced the in vivo 
tachycardia independent 11•12 and, respectively, dependent on inhibition of the 
sympathetic nervous system 11•12• Surprisingly, when rat hearts treated with aspirin 
were isolated, heart rate was still found to be reduced 13, indicating a lower intrinsic 
heart rate. However, whether reduction of MI-induced tachycardia can induce 
capillary growth in the infarcted heart needs to be established. 
The present study was designed to compare the chronic effects of four different 
treatments on in vivo and intrinsic heart rate related to capillary angiogenesis in a 
well established rat postinfarction heart failure model 14• From our previous studies 
with infarcted rats, the following treatments were selected: 1) Low-dose aspirin was 
shown to reduce in vivo heart rate without effect on left ventricular (LV) hypertrophy 
11
• 2) Methylprednisolone, an anti-infiammatory drug, has previously been shown to 
prevent hypertrophy after MI. 3) Moxonidine, a centrally-sympatholytic, was shown 
to suppress sympathetic outfiow with normalized MI-induced in vivo tachycardia, and 
prevent hypertrophy 12 4) The ACE-inhibitor captopril increased MI-induced in vivo 
tachycardia and has been reported to prevent LV hypertrophy 15• 
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6.2. Methods 
Male Wistar rats (Harlan, Zeist, The Netherlands) weighing 260-330 g were 
housed in groups of 2 or 3 on a 12 h light-dark cycle with standard rat chow and 
water available ad libitum. The experimental protocol was approved by the University 
ethics committee for the use of experimental animals and conformed with the Guide 
for care and Use of Laboratoy Animals. 
6.2.1. Myocardial infarction 
Rats were subjected to sham surgery or coronary artery ligation. Under 
pentobarbital anesthesia (60 mg/kg i.p.), MI was induced by ligation of the left 
anterior descending coronary artery. Briefly, after intubation of the trachea an 
incision was made in the skin overlying the fourth intercostal space, with the 
overlying muscles separated and kept aside. The animals were put on positive 
pressure ventilation (frequency 65-70/ min, tidal volume 3 ml) and the thoracic cavity 
was opened by cutting the intercostal muscles. The heart was carefully pushed to the 
left and 6-0 silk suture was looped under the left descending coronary artery near 
the origin of the pulmonary artery. After returning the heart to its normal position, 
the suture was tied. Intercostal space was closed by pulling the ribs with 3-0 silk, the 
muscles were returned to their normal position and the skin incision was sutured. 
Sham-operated animals underwent the same surgical procedure, without the actual 
coronary artery ligation. Proper occlusion of the coronary artery resulted in an 
extensive transmural infarction comprising a major part of the LV free wall, with 
small variations in size 15• Infarct size was determined by planimetry at mid-
ventricular levels in transverse slices 16 as the percentage of LV circumference 13• 
6.2.2. Treatments 
MI-rats were randomized to receive treatment with low-dose aspirin, 
methylprednisolone, moxonidine or captopril. Low-dose aspirin (25 mg/kg; lysine-
acetylsalicylic, Aspegic®, Lorex B.V., Maarssen, The Netherlands) 13 and 
methylprednisolone (5 mg/kg; methylprednisolone sodiumsuccinate, Solu-Medrol®, 
Pharmacia&Upjohn, The Netherlands) 17 were dissolved in saline and administered as 
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daily i.p. injections of 1 ml/kg. This dose of aspirin is shown to reduce platelet 
production of pro-aggregatory and vasoconstrictor thromboxane in favour of anti-
aggregatory and vasodilator prostaglandins without exerting anti-inflammatory 
activity 18 Whereas aspirin treatment was started 2 days before surgery and 
continued until the end of the experiment at 21 days after surgery, 
methylprednisolone was started at the end of the acute inflammatory phase 14 at 7 
days post-MI and also continued to 21 days after surgery. Untreated control rats 
were receiving once daily saline injections of 1mljkg i.p. from 2 days before until 21 
days after surgery (control for asprin treatment) or from 7 days to 21 days after 
surgery (control for methylprednisolone treatment). 
The centrally-acting sympatholytic moxonidine (Solvay Pharma, Hannover, 
Germany) was dissolved in accidified saline to provide a final daily dose of 6 
mg/kg/day using subcutaneously implanted osmotic minipumps (Aizet"' 2001, ALZA 
Pharmaceuticals, Palo Alto, CA, USA) 12• Administration of moxonidine was started 
24 h following Ml and continued until the end of the experiment at 21 days after 
surgery. Minipumps were replaced each week under ether anesthesia. Sham-rats and 
untreated Ml-rats underwent the same anesthesia and surgical procedure without 
the actual implantation of the minipumps. 
The ACE-inhibitor, captopril (Squibb, Princeton, NJ, USA), was dissolved in the 
drinking water (2g/l) 19•20, 24 h after Ml and continued until the end of the 
experiment, at 21 days after surgery. 
6.2.3. In vivo heart rate and mean arterial pressure 
At day 19 after coronary artery ligation, rats were re-anesthetized with sodium 
pentobarbital and a catheter (PE-10 heat-sealed to PE-50) was inserted in the 
abdominal aorta through the femoral artery. The heparinized saline filled catheter 
was tunneled under the skin, exteriorized at the back of the neck and closed with a 
metal plug. The animals were housed separately and allowed to recover 2 days 
before measurements. On the experimental day, the arterial catheter was connected 
to a pressure transducer (Viggo-spectramed, DT-XX, Bilthoven, The Netherlands) and 
signal was fed into a 68809-based microprocessor and compatible computer, 
sampling at 500 Hz. After 1 h stabilization, baseline values of mean arterial blood 
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pressure and heart rate were obtained. Heart rate was measured as the frequency of 
the pulsatile aortic pressure signal. 
6.2.4. Isolated heart perfusion 
At the end of the protocol, the hearts were rapidly excized under pentobarbital 
anesthesia and mounted for perfusion with an oxygenated Krebs-Henseleit buffer 
(composition in mM: NaCI 125, KCI 4.7, caCI2 1.35, NaHC03 20, NaH2P04 0.4, D-
glucose 10; pH=7.4; 37°C) at a constant pressure of 85 mmHg, using the 
Langendorff technique. Isolated hearts were allowed to beat spontaneously. LV 
function was measured as the isovolumetric developed pressure against a fluid-filled 
latex balloon placed in the left ventricle, connected to a miniature low-volume 
displacement pressure transducer. LV end-diastolic pressure was set to 5 mmHg by 
adjusting the balloon volume. Coronary flow was measured by a flow probe 
(Transonic Systems, Ithaca, NY, USA) placed in the tubing just before the ostia of the 
coronary arteries. cardiac perfusion was defined as the coronary flow corrected for 
ventricular weight. Coronary vasodilator reserve, reflected by maximal coronary flow, 
was obtained with 0.1 ml of 10·2 M sodium nitroprusside solution (University Hospital 
pharmacy) injected into the perfusing buffer just before entering the coronary 
arteries. After 15 min stabilization, baseline heart rate and LV function were 
recorded. 
6.2.5. Left ventricular hypertrophy 
After completion of the functional measurements, hearts were removed from 
the Langendorff preparation and weighed after exclusion of the atria and large 
vessels. Ventricular hypertrophy was indicated as the ratio of ventricular weight to 
body weight. \entricles were cut into 4 transversal slices from apex to base and 
fixated with 3.6% phosphate-buffered formaldehyde for at least 24 h. After fixation, 
the slices were dehydrated and paraffin-embedded. Deparaffinized 5 J.lm thick 
sections were stained with a Gomori's silver staining 21 in order to visualize individual 
myocytes of the viable LV wall. Concentric myocyte hypertrophy in the viable LV free 
wall, remote from the infarcted area, was measured as the cross-sectional area of 
transversally cut myocytes showing a nucleus using image analysis (Zeiss KS 400, 
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Germany). Myocyte density was calculated as the average number of myocytes per 
tissue area. 
6.2.6. Capillary density 
To visualize capillaries in the myocardium, endothelial cells were stained with 
Lectin GSI (Sigma-Aldrich Chemie©, Zwijndrecht, The Netherlands), as previously 
described by Nelissen-Vrancken et a/. 16• Sections of 5 ).!m thickness were 
deparaffinized and rehydrated, and endogenous peroxidase was inhibited by 
methanoljH,o, (0.3%) for 15 minutes. The sections were incubated overnight with 
the biotinylated Lectin GSI (1:100) at room temperature. Then, in a second step, the 
signal was intensified with an ABC-complex containing peroxidase labeled biotins 
(1:100) (Lab vision, CA, USA). Finally, the sections were incubated with a Ni-Co 
amplified DAB solution to which a stable peroxide substrate buffer was added 
(Pierce©, USA). Endothelial cells of capillaries and larger vessels are visualized in the 
myocardium as a brown precipitate. A background staining was not used in order to 
avoid interference with the Lectin staining. The number of capillaries were counted in 
the same region of the viable LV free wall in which myocyte area was determined. 
Image analysis (Zeiss KS 400, Germany) was used to measure capillary density, 
calculated as the number of capillaries per tissue area in the viable LV wall. Capillary 
to myocyte ratio was calculated as capillary density divided by myocyte density. 
6.2.7. Data analysis 
All data are presented as means ± S.E.M. Data of infarcted rats were only 
included if the infarction comprized the major part of the LV free wall, since small 
infarctions ( <20%) are found to be hemodynamically fully compensated 4•22• 
Estimation of infarct size by macroscopic appearance has proven to be a reliable 
method to recognize too small infarctions ( <20 %) 15• Because of temporal variation 
and different control administration, each treatment group had its own sham and 
untreated infarct controls. Statistical analysis of effects of treatment was performed 
within each group using one-way analysis of variance (ANOVA) (SigmaStatTM, Jandel 
Scientific, Erkrath, Germany) followed by Bonferroni's post-hoc t-tests for multiple 
group comparisons 23• Differences were considered statistically significant if P<0.05. 
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6.3. Results 
Overall mortality following MI was 39 % and did not depend on treatment, 
since death mainly occurred within the first 24 h after coronary artery ligation. No 
other than surgery related death was observed during the treatment period. Data 
from four different treatment groups were collected: low-dose aspirin (n=6-12), 
methylprednisolone (n=7-12), moxonidine (n=7-14) and captopril (n=7-10) treated 
MI-rats . 
6.3.1. Functional parameters 
Hemodynamics obtained from conscious rats as well as isolated perfused 
hearts are summarized in Table 1. Mean arterial pressure was similar for all groups, 
except captopril treated Ml-rats, which displayed a lower mean arterial pressure 
compared to untreated Ml-rats. In vitro LV dysfunction of Ml-hearts was reflected by 
a significantly reduced LV systolic pressure, which was not affected by treatment. 
Coronary flow corrected for ventricular weight (cardiac perfusion) as well as maximal 
coronary flow obtained with sodium nitroprusside were similar in all experimental 
groups. 
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Table 1. LV functional parameters obtained from conscious rats and isolated 
perfused hearts at 21 days after surgery 
Experimental groups ASP MP MOX CAP 
n 6-12 7-12 7-14 7-10 
li1.JtjJ[Q 
MAP (mmHg) Sham 106±2 115±2 112±2 133±2 
MI 99±4 108±4 98±3 127±7 
Ml+ 96±2 99±3 100±5 101±4 a b 
In vitro 
LV systolic pressure Sham 75±5 89±6 77±6 94±6 
(mmHg) MI 51±4 a 58±6 a 51±7 a 74±7 a 
Ml+ 49±4a 78±7 44±5 a 77±14a 
Cardiac perfusion Sham 10.6±0.6 10.3± 0.7 8.6±0.9 9.5±1.4 
(mljmin.g) MI 8.9±1.0 8.7±1.0 . 6.6±.0.8 7.4±0.6 
MI+ 9.8±1.4 7.3± 0.6 9.4±0.8 8.1±1.1 
Maximal CFn;troprus<d.Sham 19.1±1.1 21.9±1.5 19.9±1.0 20.7±0.7 
(mljmin) MI 17.8±2.2 22.7±1.4 21.8±0.9 19.9±0.9 
MI+ 17.8±1.1 19.8±1.1 19.2±1.3 20.1±0.8 
Data are presented as means±S.E.M. MI: untreated infarcted rats; MI+: treated infarcted rats; ASP: 
aspirin ; MOX: moxonidine; MP: methylprednisolone; CAP: captopril; MAP: mean arterial pressure; LV: 
left ventricular; CF: coronary flow; a P<O.OS vs. SHAM; bP<O.OS vs. MI 
Values for in vivo (upper panel) and intrinsic (lower panel) heart rate are represented 
in Fig. 1. Untreated conscious MI-rats of all groups were characterized by a marked 
in vivo tachycardia, which was normalized to sham-values with aspirin, moxonidine, 
and methylprednisolone. In case of captopril a further increase rather than 
normalization of in vivo heart rate was observed. Accordingly, intrinsic heart rate 
measured in isolated perfused hearts was significant higher in untreated Ml- than 
sham-hearts. Treatment with aspirin and methylprednisolone, but not moxonidine or 
captopril, resulted in normalization of intrinsic heart rate to sham-values. 
122 
Chapter 6 
600 
500 
" 
.§ 
en 400 
1ii 
" .0 300 
200 
400 
.E 3oo 
~ 
iii 
~ 200 
100 
in vivo heart rate 
* 
intrinsic heart rate 
* # 
Heart rate and capillary angiogenesis 
• 
c:::J Sham 
-MI 
fS:SS] Aspirin 
ezz.l Methylprednisolone 
E3 Moxonidine 
~ Captopril 
Fig. 1. In vivo (upper panel) and intrinsic heart rate (lower panel) obtained from conscious rats and 
isolated heart perfusions, respectively.*: P<O.OS vs Sham;#: P<O.OS vs MI. 
6.3.2. LV hypertrophy 
Three weeks after surgery, infarct size as well as body and ventricular weight 
were measured for the different groups (Table 2). Infarct size in untreated and 
treated MI-hearts was similar in all groups. Whereas a lower body weight was 
observed in untreated MI-rats of the aspirin group compared to sham-rats, 
moxonidine and captopril treated MI-rats manifested a lower body weight compared 
to untreated MI-rats. Ventricular weight of untreated MI-rats in the 
methylprednisolone, moxonidine and captopril group was significantly higher than 
sham-operated control hearts despite replacement of the major part of the left 
ventricular free wall by lighter scar tissue. Moreover, treatment with 
methylprednisolone, moxonidine and captopril, but not aspirin, normalized ventricular 
weight to sham-values. In addition, ventricular weight to body weight ratio, reflecting 
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total ventricular hypertrophy, was increased in untreated MI-rats of all groups, and 
normalized with moxonidine. Increased ventricular weight to body weight ratio in 
untreated MI-rats of the aspirin group is explained by a lower body weight of these 
rats 3 weeks after MI. 
Table 2. Infarct size, body and ventricular weight measured in the different 
experimental groups 21 days after surgery 
Experimental groups ASP MP MOX CAP 
n 6-12 7-12 7-14 7-10 
Infarct size(%) Sham 
Ml 37± 1 43± 2 45±3 41± 5 
Ml+ 39± 3 41±3 44±3 39±4 
Body weight (g) Sham 376± 6 346± 8 333± 7 368±5 
MI 340±7a 347± 8 320±10 359±4 
Ml+ 335±8 300± 10 b 299± 9 b 334±4° 
Ventricular weight Sham 1060±19 1061±52 1174±37 1071± 21 
(mg) MI 1098±35 1211±54a 1543±75a 1232±56a 
Ml+ 1147±39 1059±64° 1076±24° 1033±41 b 
Ventricular weight Sham 2.8±0.1 3.1±0.1 3.5±0.1 2.9±0.1 
I body weight (mg/g)MI 3.3±0.1a 3.5±0.1 a 4.7±0.3 a 3.5±0.2 a 
MI+ 3.4±0.1 3.5±0.1 3.6±0.2 b 3.1±0.1 
Data are presented as means±S.E.M. MI: untreated infarcted rats; MI+: treated infarcted rats; ASP: 
aspirin; MOX: moxonidine; MP: methylprednisolone; CAP: captopril; LV: left ventricular; a P<O.OS vs. 
SHAM; Dp<Q.OS vs. MI 
Representative photomicrographs of Gomori stained sections in the LV viable wall are 
shown in Fig.2. MI-induced LV hypertrophy at cellular level, which was confirmed by 
a significantly increased myocyte cross-sectional area, was prevented in moxonidine, 
methylprednisolone and captopril treated MI-hearts. 
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Fig. 2 
SHAM 
Gomori stained sections in the LV viable wall of sham-hearts, untreated and treated 
MI-hearts, showing individual myocytes. The bar in left upper photomicrograph 
indicates 100 IJffi, and accounts for all micrographs. ASP: aspirin ; MOX: moxonidine; 
MP: methylprednisolone; CAP: captopril. 
These observations were substantiated by the actual measurements as presented in 
Fig.3. 
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Fig. 3. Actual measurements for myocyte cross-sectional area in the different experimental 
groups. *: P<O.OS vs Sham; #: P<O.OS vs MI. 
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6.3.3. Capillary density 
Photomicrographs of Lectin stained sections in the LV viable wall showing 
individual capillaries are represented in Fig.4. A significantly reduced capillary density 
observed in Ml-induced hypertrophied hearts, was normalized to sham-values with 
moxonidine, methylprednisolone and captopril and even increased above sham-
values with aspirin. 
fig. 4. 
Ml 
Lectin stained sections in the LV viable wall of sham~hearts, untreated and treated MI-
hearts, showing individual capillaries (small dark brown circles). The bar in left upper 
photomicrograph indicates 100 11m, and accounts for all micrographs. ASP: aspirin ; 
MOX: moxonidine; MP: methylprednisolone; CAP: captopril. 
These observations were substantiated by the actual measurements in Fig.S (upper 
panel}. Whereas capillary to myocyte ratio remained unchanged in moxonidine and 
captopril treated MI-hearts, it was almost doubled in aspirin and methylprednisolone 
treated Ml-hearts (Fig.S, lower panel). 
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Actual measurements for capillary density (upper panel) and capillary to myocyte ratio 
(lower panel) in the different experimental groups. *: P<O.OS vs Sham; #: P<O.OS vs 
MI. 
6.4. Discussion 
6.4.1. LV function and heart rate 
In the present study, LV dysfunction of isolated Ml-hearts was refiected by a 
decreased in vitro LV systolic pressure, which was not significantly improved by 
either treatment. Furthermore, chronically infarcted rats were characterized by a 
marked in vivo tachycardia. Whereas treatment with aspirin, methylprednisolone and 
moxonidine normalized Ml-induced in vivo tachycardia, captopril further increased in 
vivo heart rate of Ml-hearts. The latter observation with captopril is in accordance 
with previous functional observations in early captopril treated rats 4, whose hearts 
displayed a decreased LV developed pressure and depressed peak velocity of 
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contraction 20 • In order to maintain cardiac output at a lower LV function in these 
hearts, heart rate needs to be increased. 
Interestingly, when hearts of untreated MI·rats were isolated and perfused, 
thereby circumventing influence of sympathetic nerve activity and circulating 
catecholamines as the major determinants of in vivo heart rate, their heart rate was 
found to be still higher than in sham-operated hearts. This may indicate changes in 
intrinsic activation of the sinus node as was suggested by Schoemaker et al. 11• The 
presence of local sympathetic activity that could have remained after isolation was 
excluded by the absence of heart rate response to 10·6 M propranolol (data not 
shown). Chronic treatment with aspirin and methylprednisolone, but not moxonidine 
and captopril, normalized the increased intrinsic heart rate of isolated MI·hearts. 
Hence, the lower in vivo heart rate observed with aspirin and methylprednisolone 
might be due to a reduced intrinsic heart rate rather than to a suppressed 
sympathetic nervous system activity. This explanation is further supported by 
unchanged plasma catecholamine concentatrions in aspirin 11 and 
methylprednisolone treated rats (data not shown). In case of moxonidine, a clear 
relation between sympathetic suppression and reduced in vivo heart rate has been 
previously demonstrated in experimental 12 and clinical studies 24•25. However, 
moxonidine was not found to reduce intrinsic tachycardia in isolated MI·hearts. 
The mechanism by which the intrinsic heart rate in aspirin and 
methylprednisolone treated MI·hearts was reduced, might be explained as a 
reflection of the effects of treatment on the cardiac remodeling process 13. In one 
study, a correlation between sinus node activity and collagen modulated by stretch 
was suggested 26• Since aspirin and methylprednisolone have been shown to 
interfere with collagen deposition in the surviving myocardium of infarcted rats 17, we 
cannot exclude the possibility that collagen of the sinus node was also affected. 
However, also moxonidine 12 and ACE-inhibitors 27 have been shown to inhibit 
collagen deposition in the spared myocardium, without reducing intrinsic heart rate. 
6.4.2. Left ventricular hypertrophy and capillary adaptation 
The heart responds to overload following MI with an adaptive hypertrophic 
reaction, which is aimed to restore the myocardial function and normalize increased 
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wall stress. Hypertrophied cardiomyocytes in the spared myocardium are 
characterized by a decreased capillary surface and increased diffusion distance for 
oxygen. The present results concerning morphometric indices, clearly demonstrated 
a Ml-induced hypertropic response of the spared myocardium, which was associated 
with a decreased number of capillaries per tissue area. This is in accordance with 
previous observations in infarcted rats, which were characterized by a decreased 
capillary and myocyte density 2•28• It appears that despite the increased 
cardiomyocyte cell volume, capillary number per myocyte remains unaltered, and, 
hence, probably insufficient for adequate oxygenation of hypertrophied 
cardiomyocytes 29 • Microvascularization in remodeled Ml-hearts can be improved by 
inhibition of reactive compensatory hypertrophy. This was recently confirmed in 
moxonidine treated Ml-rats, which manifested a restored capillary density associated 
with improved ischemic tolerance as a consequence of prevented LV hypertrophy 
(Van Kerckhoven, submitted). Whereas in the present study, prevention of 
compensatory hypertrophy was confirmed by a normalized myocyte area in 
methylprednisolone, moxonidine and captopril treated MI-hearts, aspirin did not 
affect LV hypertrophy at all. Normalization of hypertrophy in methylprednisolone, 
moxonidine and captopril Ml-hearts was associated with a restored capillary density 
in the spared myocardium. Surprisingly, although aspirin did not prevent 
compensatory hypertrophy, capillary density was even increased above sham-values 
suggesting capillary angiogenesis rather than restored capillary density. These 
findings were fully supported by the values of capillary to myocyte ratio, which were 
doubled when compared sham-hearts. capillary angiogenesis indicated by a 
significantly increased capillary to myocyte ratio, was also observed in 
methylprednisolone treated MI-hearts, although to a lesser extent than aspirin 
treated MI -hearts 
6.4.3. Interaction between heart rate and capillary growth 
Independent of its origin, bradycardia is associated with capillary growth 6, which 
could provide high clinical benefit. Capillary angiogenesis has been shown by either 
bradycardia I pacing 7•30 or infusion of bradycardic drugs such as alinidine 5•31• A lower 
in vivo heart rate was shown to improve the balance between oxygen demand and 
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supply by enhanced tissue perfusion through longer diastolic time 32 in addition to 
the increased myocardial capillarization 6•7 • However, a distinction should be made 
between restored capillary density as a direct result of prevention of LV hypertrophy 
and actual growth of new capillaries. The latter phenomenon was most pronounced 
in aspirin and subsequently, methylprednisolone treated MI-hearts. These hearts 
happen to display lower intrinsic heart rates. Restored capillary density resulting from 
prevented hypertrophy seems to be the case in both moxonidine and captopril 
treated Ml-hearts, since capillary to myocyte ratio remained unchanged. Similar 
findings were observed in spontaneously hypertensive rats with the ACE-inhibitor 
temocapril 33• An interaction between lower intrinsic heart rate and cardiac 
capillarization has been suggested from studies with exercise training induced 
bradycardia 34•35 • Whereas heart rate after autonomic blockade (intrinsic heart rate) 
was shown to be reduced as a part of adaptation to training 36, morphometric 
measurements in exercise induced hypertrophied pig hearts have revealed 
compensated capillary proliferation 37• From the present study, we may conclude that 
a lower intrinsic heart rate in aspirin and methylprednisolone treated Ml-hearts could 
be responsible for observed capillary angiogenesis, as indicated by an increased 
capillary to myocyte ratio. In addition, capillary angiogenesis in aspirin treated Ml-
hearts may be an attractive explanation for the improved in vivo hemodynamics, 
which was observed in aspirin treated Ml-rats 11• However, the exact mechanism by 
which a lower intrinsic heart rate is associated with capillary angiogenesis, remains 
yet unclear. Both mechanical factors, such as stretch of the capillary wall, or 
treatment induced release of growth factors stored in the capillary basement 
membrane 6 may play a role. Indeed, the vascular endothelial growth factor or VEGF, 
was shown to play a key role in bradycardia induced angiogenesis 5• Furthermore, 
possible synergism between steroids and basic fibroblast growth factor was shown to 
improve capillary density in rats with spinal cord injury 38. 
6.4.4. Conclusions 
The present results show that pharmacological induced prevention of left 
ventricular hypertrophy normalizes capillary density without affecting capillary 
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number. Furthermore, normalized intrinsic rather than in vivo tachycardia may 
contribute to actual capillary angiogenesis in chronically infarcted hearts. 
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7 .1. General discussion 
Heart failure is no longer conceptualized as a pure hemodynamic disorder. 
Rather, the syndrome of heart failure is a more complex interplay of hemodynamic 
changes, neurohormonal activation and structural changes in the heart itself. The 
loss of ventricular function is usually preceded by an initiating event such as 
myocardial infarction, which leads to activation of specific neurohormonal systems 
such as sympathetic nervous system, renin-angiotensin system and arginin 
vasopressin system. Myocardial infarction is a leading cause of heart failure, which is 
associated with a 10-fold greater risk of developing heart failure compared with a 
normal population 1• The neurohormonal hypothesis postulates that neurohormones 
are initially adaptive by maintaining cardiac output and blood pressure, but later the 
same compensatory responses become pathological by increasing cardiac loading 
conditions and contribute to adverse remodeling, progressive ventricular failure, and 
ultimately to the syndrome of heart failure 2• 
Acute loss of myocardium after myocardial infarction results in an abrupt 
increase in loading conditions that induces a unique pattern of remodeling involving 
the infarcted border zone and remote non-infarcted myocardium. These structural 
changes or remodeling include abnormal myocyte growth (hypertrophy), proliferation 
of cells in the extracellular matrix, and myocyte cell loss which finally contribute to 
deterioration of ventricular function. These processes of remodeling have taken on 
increasing importance with the recognition that pharmacological interference could 
favourably affect the remodeling process and thereby reduce cardiovascular 
morbidity and mortality when administered in the later postinfarction period. 
Postinfarction remodeling is a time-dependent process, but the time course and 
effects of interference, particulary the early time course, has not been completely 
elucidated. Therapy during the different phases of the remodeling process require 
different strategies. In the past, pharmacological research has mainly focused on 
therapeutic intervention in the decompensation phase when congestive heart failure 
is diagnosed and prognosis becomes very poor. However, although still patients at 
the decompensation stage are clinically the most important ones, inclination towards 
intervention during the early postinfarction period (in which a major part of 
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remodeling occurs) is growing. One of the problems that may arise, however, is that 
earlier treatment is aimed at the opposite direction as the later therapy. This problem 
is substantiated by the results of the 2 CONSENSUS trials, in which delayed 
treatment with ACE-inhibitors had clearly beneficial effects (CONSENSUS I), whereas 
similar treatment during early phases had detrimental effects (CONSENSUS II)3. 
During the early stages after myocardial infarction, cardiac hypertrophy and 
remodeling have become a major target for therapy since they are associated with 
improved prognosis at later stages (SOLVD investigators). When treatment should be 
started earlier, that is with ventricular dysfunction but before signs of heart failure, it 
implies interference with cardiac hypertrophy and remodeling, which during the early 
phase are regarded a pathophysiological response to compensate for the loss of 
contractile tissue. This indicates that pharmacological therapy should therefore be 
selected carefully 3•4• In the light of these observations we hypothesized that 
treatment during this early phase should be directed to preserved total amount of 
contractile tissue of the non-infarcted myocardium, with optimal perfusion. 
Pharmacological interference with early postinfarction remodeling may induce major 
changes in cardiac architecture such as the collagen network, hypertrophic reponse 
of cardiomyocvtes. microcirculation. and subsequently metabolic regulation. 
7.1.1. Interference with collagen network 
Collagen accumulation in the non-infarcted tissue is a potential target for 
treatment since it has been related to increased myocardial stiffness and impaired 
diastolic heart function. In early postinfarction remodeling, structural alterations of 
the collagen network are associated with infarct expansion and left ventricular 
dilation 5•6• Later in the course of postinfarction remodeling, infarcted tissue is 
replaced by scar tissue with a high collagen content while in the non-infarcted tissue 
collagen content is increased as well 7•8• However, a too large reduction of the tensile 
strength of the left ventricular collagen network could result in aggravation of 
chamber dilation, as has been reported with non-steroid anti-inflammatory drugs and 
steroids 9•10• The above suggestions were confirmed in chapter 2, in which early 
aspirin and methylprednisolone treatment were shown to interfere with collagen 
deposition in the non-infarcted myocardium rather than in the infarct scar, resulting 
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in an altered left ventricular diastolic function. Furthermore, prevention of interstitial 
collagen build-up in the non-infarcted myocardium after myocardial infarction, as 
observed with methylprednisolone but not aspirin, promoted left ventricular dilation 
without affecting diastolic stiffness, but also improved active relaxation. Thus, based 
on these results we conclude that early interference with the collagen build-up in the 
non-infarcted myocardium may induce detrimental effects by promoting left 
ventricular dilation, but also beneficial effects by improving left ventricular relaxation. 
7.1.2. Interference with compensatory hypertrophy 
Pharmacological treatment during the early phase after myocardial infarction 
may have profound effects on the compensatory hypertropic response of the non-
infarcted myocardium and cardiac function as was previously reported with ACE-
inhibitors. In a study that compared effects of early and late treatment with captopril, 
it was shown that late treatment had beneficial effects but early treatment even may 
have deleterious hemodynamic effects 4• This was supported by the clinical enalapril 
studies using mortality as outcome (CONSENSUS I an II). Early captopril treatment 
prevented hypertrophy, interstitial fibrosis in the spared myocardium 11, and reduced 
coronary reserve. Because in vivo hemodynamic measurements even showed 
deterioration after this early treatment, it was concluded that preventing all 
processes during this early phase may not be very effective in preventing heart 
failure. Maybe part of the remodeling can be regarded as beneficial and part as 
detrimental, and a more subtle intervention is required. That prevention of early 
compensatory hypertrophy may not be advantageous in terms of improving cardiac 
function was supported by the functional results of early treatment with moxonidine 
(Chapter 3) and captopril (Chapter 6). On the contrary, preserved compensatory 
hypertrophy, as was observed with aspirin (Chapter 2) and V1A vasopressin 
antagonist (Chapter 5) could be one of conditions to restore cardiac function in the 
infarcted heart. 
7 .1.3. Interference with vascularization 
A second part of our hypothesis stated that preserved hypertrophy should be 
accompanied with optimal perfusion. Early investigations have reported a decreased 
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capillary supply to the surviving hypertrophic myocytes in the early as well as late 
phases after myocardial infarction 12• Normalization of the relation between cardiac 
muscle growth and vascular growth is associated with improved function of the non-
infarcted myocardium, and may thus beneficially affect clinical outcome 13. 
Vascularization in remodeled infarcted hearts can be improved by inhibition of 
reactive hypertrophy, direct stimulation of vascular growth using growth factors or 
indirectly by reducing heart rate. The present thesis showed that all treatments 
which did prevent early compensatory hypertrophy ( captopril, moxonidine, 
methylprednisolone) (Chapter 6) were, hence, able to normalize capillary density 
(number of capillaries per tissue area). Restored capillary density in the non-infarcted 
myocardium of these hearts could be explained as result of prevented hypertrophy 
rather than actual growth of capillaries, since capillary to myocyte ratio remained the 
same. This explanation was further supported by other experimental studies using 
AT1 receptor antagonists 14•15• A restored capillary density following prevention of 
hypertrophy may have beneficial effects on the ischemic tolerance of the non-
infarcted myocardium, as was shown for moxonidine (Chapter 4) and captopri1 16• 
Since a preserved hypertrophic response after myocardial infarction may be 
essential to support cardiac function, optimal perfusion must be achieved by 
stimulation of capillary growth (angiogenesis). Several ways to stimulate capillary 
growth in the non-infarcted myocardium have been described: 
1. Locally adminiStration of growth factors : 
A number of growth factors are candidates for therapeutic augmentation of 
myocardial perfusion. These include vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), transforming growth factor-~ (TGF-~) and insulin-like 
growth factor. Although angiogenesis is therapeutically desirable in the infarcted 
heart, one problem that may arise is that these growth factors need to be delivered 
locally, and not systemically, to avoid possible tumor formation 17• Another strategy 
to administer growth factors involves the introduction of genes encoding these 
factors 18• However, preliminary evidence suggests that prolonged local production of 
potent growth factors such as VEGF and bFGF may cause unwanted hemangioma 
formation or fibromatosis 19• Moreover, the theoretical advantage of gene therapy 
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approaches with respect to long-term angiogenic factor exposure depends on 
effective local expression, which is not optimal yet because of high variability in the 
level and duration of gene expression. 
2. Heart @te retiusJ;ion or br?dvcardia : 
Bradycardia appears to be a particularly good way of stimulating angiogenesis, 
because the magnitude of capillary growth is impressive. Independent of its origin, 
bradycardia is associated with capillary growth 20 which could provide high clinical 
benefit. capillary angiogenesis has been shown by either bradycardia! pacing 21 or 
infusion of bradycardic drugs such as alinidine 22• Long-term reduction of in vivo 
heart rate has been acknowledged to improve tissue perfusion by increasing diastolic 
time, while energetic efficiency is improved 23 in addition to the increased myocardial 
capillarization 24• This capillary angiogenesis in response to bradycardia appears to be 
associated with upregulation of VEGF mRNA and followed by enhanced VEGF protein 
synthesis 25• 
Since postinfarction remodeled hearts display a lower mechanical efficiency 
which may be amplified by tachycardia, pharmacological induced normalization of 
this tachycardia may have favourable effects. In vivo heart rate following myocardial 
infarction is mainly attributed to increased sympathetic nervous system activation 
and plasma noradrenaline levels. However, if these infarcted hearts are isolated and 
perfused, heart rate is also found to be increased indicating changes in intrinsic heart 
rate. Besides lowering in vivo tachycardia after myocardial infarction, reduction of 
this intrinsic heart rate by modulation of the sinus node activity may stimulate 
angiogenesis and thus, improve cardiac function. Agents such as zatebradine and 
zeneca ZD7288 have been demonstrated to slow sinus node rate, thereby decreasing 
intrinsic heart rate 26 and improving cardiac mechanics and energetics in patients 
with left ventricular dysfunction 27 . Furthermore, from the present thesis lowering 
intrinsic rather than in vivo tachycardia seems to contribute to capillary angiogenesis 
in the non-infarcted myocardium as was shown for aspirin and, to a lesser extent, 
methylprednisolone (Chapter 6). Indeed, normalization of intrinsic, but not in vivo 
tachycardia, was exclusively related to capillary growth. At least in case of early 
aspirin treatment this could explain the improved hemodynamics 3 weeks after 
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myocardial infarction. Thus, we conclude that strategies which result in reduced 
intrinsic heart rate may have benefit to optimize perfusion in the failing heart. 
However, normalization of tachycardia and associated capillary angiogenesis may not 
be the only determinant factor for improving cardiac function. This was confirmed by 
early V1A vasopressin antagonist treatment in which improved cardiac function could 
not be attributed to capillary growth. 
7.2. Conclusions and future outlook 
In the past, pharmacological research has mainly focused on relief of 
symptoms in the late decompensation phase, when congestive heart failure is 
diagnosed and prognosis becomes very poor. Except for treatment with ACE-
inhibitors, prognosis has not benefited substantially from all these research. Instead 
of aiming the regression of remodeling in the late phase, therapy early after 
myocardial infarction can be an alternative approach to prevent heart failure, but 
may include strong interference with the cardiac remodeling process. Moreover, 
different aspects of this remodeling process can be affected separately, providing a 
unique opportunity to study them distinctively. Based on previous observations with 
early and late ACE-inhibitor treatment, the results of the present thesis support our 
hypothesis that optimal treatment during the early compensatory stage after 
myocardial infarction may not interfere with left ventricular hypertrophy. Indeed, a 
distinction should be made between favourable and unfavourable remodeling, since 
the former may be a necessary physiological response to the primary myocardial 
damage. However, pharmacological induced prevention of compensatory hypertrophy 
may also have advantageous effects to the non-infarcted hypertrophied myocardium. 
These include restored capillary density and reduced ischemic vulnerability of the 
non-infarcted myocardium 28• Although these effects are undoubtedly beneficial to 
the myocardium, in vivo cardiac function seems rather to depend on the total amount 
of viable contractile tissue left. Therefore to provide optimal perfusion of the 
hypertrophied non-infarcted myocardium, improving vascularization could be one 
approach. Early pharmacological therapy that preserves hypertrophy and stimulates 
vascular growth in the non-infarcted myocardium seems to have beneficial effects on 
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hemodynamics, as shown for aspirin. However, other mechanisms besides enhancing 
vascularization may play an important role in the improvement of the failing heart. 
This was confirmed by early V lA vasopressin antagonist treatment which improved 
cardiac function independent of capillary growth. Both treatments restored infarction 
induced tachycardia, but aspirin also normalized intrinsic or in vitro tachycardia. This 
intrinsic heart rate, rather than the in vivo heart rate, was associated with actual 
capillary growth. In addition to the effects of early treatment on hypertrophic 
response and capillary growth, interference with collagen depositon in the non-
infarcted myocardium are associated with changes in left ventricular chamber 
geometry as well as diastolic function. Early treatment which interferes too much 
with collagen depostion in the non-infarcted myocardium, leads to increased left 
ventricular dilation, but at the same time can improve left ventricular relaxation. In 
conclusion, the findings of this thesis confirm our hypothesis that early treatment 
after myocardial infarction should not simply prevent cardiac remodeling. It requires 
subtle and specific interference with the remodeling process in order to improve 
contractile function of the failing heart. In the light of these observations, the role of 
new pharmacological agents interfering with specific aspects of neurohormonal 
activation and remodeling process may be promising. These include vasopressin 
antagonists, cytokine and endothelin blockers and neutralendopeptidase inhibitors 
(Fig.l). 
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Fig.l Future treatment strategies for chronic heart failure. 
Cardiorenal Cardiocirculatory Symptom relief 
model model 
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• ACE-inhibitors 
• ~-blocker 
• New antagonists Prevention of 
- NEPs? disease progression 
- Aldosterone ? 
- Endothelin ? 
- TNF? 
- Vasopressin ? 
Gene therapy ? ~ Anti-remodeling Reversal of heart 
Strategies? failure phenotype 
Even alternative therapies with the same goals, i.e. increasing viable cardiac tissue 
and optimal cardiac perfusion, are now emerging to finally improve the function of 
the failing heart. These include gene therapy enabling adenoviral gene transfection 
with vascular endothelial growth factor 1•29 or phenotypic transformation of 
embryonic stem cells into cardiomyocytes or facilitate cardiomyocyte regeneration 
and engraftment in regions of fibrosis and thinning to restore wall thickness and 
myocardial mass. Thus, all therapeutic approaches which lead to a preserved 
contractile tissue with stimulation of vascular growth may well be amenable to clinical 
application in the future. 
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The aim of this thesis was to investigate the effects of pharmacological 
interference with the different aspects of postinfarction remodeling during the ~ 
comoensatorv staae in a rat heart failure model. Ligation of the left anterior 
descending coronary artery in rats, resulting in extensive transmural infarction of the 
LV free wall, was used to study the structural and functional consequences of a large 
myocardial infarction. The rat heart failure model, which has been well established, 
is associated with left ventricular dysfunction, neurohormonal activation and 
remodeling of the cardiac structure. We hypothesized that pharmacological therapy 
should be directed to preservation of the total amount of contractile tissue with 
optimal perfusion. The former implicates that reactive hypertrophy should not be 
inhibited in this compensatory stage, whereas perfusion should be enhanced by 
increased vascularization, or optimizing the use of existing vascularization by 
prolonged diastolic time or improved cardiac relaxation. In addition, interference with 
collagen deposition afer myocardial infarction should be minimized in order to 
preserve sufficient tensile strength and prevent left ventricular dilation. 
In Chapter 1, the pathophysiology of postinfarction induced heart failure has been 
described. The different aspects of myocardial infarction induced neuroendocrine 
activation, including sympathetic nervous system, renin-angiotensin-aldosterone 
system as well as arginine vasopressin system, and 0ostinfarction remodeling in both 
infarcted and non-infarcted myocardium as well as their possible role in the transition 
from left ventricular dysfunction towards heart failure are discussed in detail. 
In Chapter 2, the effects of early interference with postinfarction induced collagen 
deposition related to left ventricular diastolic function were studied by means of 
chronic aspirin or methylprednisolone therapy. It was shown that P,armacological 
interference with aspirin and methylprednisolone may affect the deposition of 
collagen in the non-infarcted myocardium, resulting in an altered left ventricular 
diastolic function. Furthermore, changes in interstitial rather than perivascular 
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collagen seemed to be important in the regulation of passive as well as active 
relaxation of the isolated heart. 
In Chapter 3, the effects of early interference with postinfarction induced 
sympathetic activation and left ventricular remodeling (hypertrophy and interstitial 
collagen) of the non-infarcted myocardium were evaluated after treatment with the 
imidazoline I, receptor agonist moxonidine. It could be demonstrated that 
moxonidine effectively suppressed sympathetic activation following myocardial 
infarction in a dose-dependent way as was indicated by reduced heart rate and 
plasma noradrenaline levels. Furthermore, postinfarction left ventricular remodeling 
may be attenuated at a higher dose-range of moxonidine as shown by normalization 
of ventricular weight to body weight ratio and interstitial collagen deposition in the 
non-infarcted myocardium. 
In Chapter 4, the effects of early interference with myocyte hypertrophy and 
capillary density in relation to ischemic sensitivity were studied in isolated infarcted 
hearts by means of chronic moxonidine therapy. Histological analysis revealed that 
concentric hypertrophy of the non-infarcted myocardium following myocardial 
infarction, as indicated by almost double cross-sectional area of Gomori stained 
myocytes, was completely prevented by moxonidine. Although capillary to myocyte 
ratio was similar in all groups, prevention of hypertrophy with moxonidine was 
accompanied by a a restored number of Lectin stained capillaries per tissue area. 
Furthermore, ischemic sensitivity of infarcted hearts, as reftected by increased 
maximal coronary ftow during reperfusion, was reduced with moxonidine. This was 
supported by substantially lower purines and lactate concentrations in the coronary 
effluent during ischemia. It was concluded that prevention of myocyte hypertrophy 
with moxonidine may preserve capillary density without affecting actual capillary 
number, thereby improving ischemic tolerance of the spared myocardium. 
In Chapter 5, the in vivo hemodynamic effects of early treatment with a V1A- (SR-
49059) and V, (SR-1214636) receptor antagonist in chronically infarcted rats were 
studied. Improved cardiac output with the vasopressin V1A antagonist resulted both 
from an increased stroke volume and slightly reduced postinfarction tachycardia. 
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Moreover, left ventricular concentric hypertrophy associated with reduced capillary 
density in the spared myocardium of infarcted rats, remained unaffected by therapy 
with the vasopressin v,A or V2 antagonist. Thus, chronic vasopressin V1A-, but not V2 
receptor blockade was able to prevent heart failure in 3 week old infarcted rats. 
Nevertheless, the improved cardiac function in these rats could not be attributed to 
changes in left ventricular hypertrophy and/ or capillary density. 
In Chapter 4 the relation between heart rate (in vivo and intrinsic) and capillary 
angiogenesis in the non-infarcted myocardium of rats treated with aspirin, 
methylprednisolone, moxonidine and captopril in the early compensatory stage was 
investigated. While actual in vivo heart rate was measured in conscious rats, in vitro 
or intrinsic heart rate was obtained from isolated perfused hearts. Infancted rats 
manifested a significant in vivo tachycardia as well as increased intrinsic heart rate 
when compared to sham-rats. Whereas aspirin, methylprednisolone and moxonidine 
significantly reduced infarction induced in vivo tachycardia, captopril further 
increased in vivo tachycardia. Increased intrinsic heart rate in infarcted hearts was 
reduced to sham-values with aspirin and methylprednisolone, but not with 
moxonidine and captopril. In addition, prevention of left ventricular hypertrophy with 
moxonidine and captopril was shown to normalize capillary density without affecting 
capillary number, whereas aspirin and methylprednisolone normalized capillary 
density by increasing capillary number. In conclusion, normalized intrinsic (aspirin 
and methylprednisolone) rather than in vivo tachycardia after myocardial infarction 
was the suggested mechanism associated with actual capillary growth in infarcted 
hearts. 
In Chapter 7, the general discussion with concluding remarks and implications for 
future research was described. Based on the results of this thesis, we concluded that 
early treatment after myocardial infarction should not simply prevent cardiac 
remodeling. It requires subtle and specific interference with the remodeling process 
in order to improve contractile function of the failing heart. Early interference with 
postinfanction remodeling may not affect compensatory hypertrophy, but rather 
stimulate capillary growth in the non-infarcted myocardium in order to improve 
hemodynamics (aspirin). Indeed, stimulation of angiogenesis in the non-infarcted 
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hypertrophied myocardium achieved by reduction of intrinsic tachycardia in isolated 
infarcted hearts rather than in vivo tachycardia, resulted in improved hemodynamics 
(aspirin/methylprednisolone). However, other mechanisms independent of capillary 
growth may play an important role in the improvement of the failing heart, as 
observed with early v,A vasopressin antagonist therapy. In addition to the effects of 
early treatment on hypertrophic response and capillary growth, interference with 
collagen depositon was shown to affect diastolic function as well as active relaxation. 
According to our hypothesis, the results of the present thesis indicate that early 
pharmacological interference with the postinfarction remodeling process should 
oreserve contrnctile tissue and/or stimulate vascular growth in order to improve the 
function of the failing heart. 
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Deze thesis had tot doel de effecten van farmacologische interferentie met de 
verschillende aspecten van het postinfarct remodeling proces in de vroege 
compensatoire fase te bestuderen en dit aan de hand van een rat hartfalen model. 
Ligatie van de linker kransslagader resulteert in ratten in een omvangrijk transmuraal 
infarct van de linker ventrikel vrije wand, en kan gebruikt worden als model om de 
functionele en structurele gevolgen van een myocardinfarct te bestuderen. Dit rat 
hartfalen model is een goed bestudeerd experimenteel model gekarakteriseerd door 
neurohormonale activatie en remodeling van de hartstructuur zoals die bij patienten 
met hartfalen waargenomen worden. 
Onze vooropgestelde hypothese luidde dat optimale farmacologische therapie 
zich moet richten op het behoud van de totale hoeveelheid contractiel weefsel met 
een optimale oerfusie. Dit impliceert dat reactieve hypertrofie in de vroege 
compensatoire fase niet dient te worden geremd maar eerder dat perfusie van het 
resterend myocardweefsel verbeterd dient te worden door stimulatie van vaatgroei. 
Anderzijds, dient interferentie met collageen afzetting na myocardinfarct minimaal te 
zijn teneinde voldoende reksterkte te garanderen alsook verdere dilatatie van het 
linker ventrikel te voorkomen. 
In hoofdstuk 1 werd de pathofysiology van postinfarct ge"induceerd hartfalen 
beschreven. De verschillende aspecten van neuroendocriene activatie (sympathisch 
zenuwstelsel, renine-angiotensine-aldosterone en arginine-vasopressine systeem) na 
myocardinfarct, en de verschillende aspecten van het postinfarct remodeling proces 
in het ge"infarceerd en niet-geinfarceerd myocard alsook de mogelijke rol in de 
evolutie van linker ventrikel dysfunctie naar hartfalen worden gedetailleerd 
beschreven. 
In hoofdstuk 2 werden de effecten bestudeerd van vroege farmacologische 
interventie met de collageen afzetting na myocardinfarct en gerelateerd aan linker 
ventrikel diastole functie aan de hand van chronische therapie met een lage dosis 
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aspirine of stero"idbehandeling met methylprednisolone. Er werd aangetoond dat 
vroege farmacologische (aspirine en methylprednisolone) interferentie de collageen 
afzetting in het niet-ge"infarceerd myocard be"invloed en hierdoor linker ventrikel 
diastole functie verandert. De veranderingen in het interstitieel eerder dan 
perivasculair collageen bleken belangrijk te zijn in de regulatie van zowel passieve als 
actieve relaxatie van het ge"isoleerde hart. 
In hoofdstuk 3 werden de effecten geevalueerd van een vroege interferentie met 
sympathische activatie en linker ventrikel remodeling (met name hypertrofie en 
interstitieel collageen afzetting) na myocardinfarct aan de hand van chronische 
behandeling met de imidazoline I1 receptor agonist moxonidine. Er werd aangetoond 
dat moxonidine op een dosis afhankelijke manier de postinfarct ge"induceerde 
sympathische activatie na myocardinfarct kan onderdrukken, dewelke bevestigd werd 
door een verlaging van tachycardie en plasma noradrenaline spiegels. Verder werd 
aangetoond dat postinfarct remodeling geattenueerd kan worden met een hogere 
dosis moxonidine dewelke bevestigd werd door een normalizatie van de ventrikel- en 
lichaamsgewicht ratio alsook interstitiele collageen afzetting in het niet-ge"infarceerd 
deel van het myocard. 
In hoofdstuk 4 werden de effecten bestudeerd van vroege interferentie met 
cellulaire hypertrofie en capillaire dichtheid in relatie tot de gevoeligheid voor 
ischemie in ge"isoleerde infarct harten en dit aan de hand van chronische behandeling 
met moxonidine. Histologische analyse bracht aan het Iicht dat concentrische 
hypertrofie in het niet-ge·infarceerd myocard, dewelke bevestigd werd door een bijna 
verdubbeling van de hartspierceloppervlakte, vollledig geremd kon worden door 
moxonidine therapy. Hoewel de capillair myocyte ratio ongewijzigd bleef in de 
verschillende groepen, ging preventie van hypertrofie gepaard met een herstel in het 
aantal capillairen per weefseloppervlakte. De gevoeiligheid voor ischemie in de 
onbehandelde infarct harten, dewelke bevestigd werd door een toename in maximale 
coronair flow gedurende reperfusie, werd gereduceerd na chronische behandeling 
met moxonidine. Dit werd verder ondersteund door de lagere purine en lactaat 
concentraties in het coronair effluent gedurende ischemie. Er werd geconcludeerd 
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dat remming van hypertrofie na moxonidine behandeling gepaard gaat met een 
herstel in capillaire dichtheid zonder wijziging van het aantal capillairen en als gevolg 
hiervan de gevoeligheid voor ischemie venmindert in het gespaarde deel van het 
myocard. 
In hoofdstuk 5 werden de in vivo hemodynamische effecten bestudeerd van een 
vroege behandeling met een v,. (SR-49059) en V2 (SR-1214638) receptor antagonist 
in chronisch ge"infarceerde ratten. Een verbetering van het hartdebiet 
(=hartfrekwentie x slagvolume) waargenomen met de V1A antagonist resulteerde uit 
een toename in slagvolume en reductie in postinfarct tachycardie. Verder werd 
aangetoond dat linker ventrikel hypertrofie die gepaard gaat met een lagere capillaire 
dichtheid in het gespaarde deel van het myocard, niet beTnvloed werd door vroege 
behandeling met de V1A of v, antagonist. Gebaseerd op deze resultaten werd 
geconcludeerd dat chronische v,.- ,maar niet v, blokkade, in staat is myocardinfarct 
geTnduceerd hartfalen te remmen. De opmerkelijke verbetering van hartfunctie in 
deze ratten kon niet worden toegeschreven aan eventuele structurele veranderingen 
in linker ventrikel hypertrofie en/of capillaire dichteid . 
In hoofdstuk 6 werd de relatie tussen hartfrekwentie Qn vivo en intrinsieke) en 
capillaire groei in het gespaarde deel van het myocard bestudeerd in infarct ratten 
behandeld met aspirine, methylprednisolone, moxonidine en captopril in de vroege 
compensatoire fase. In vivo hartfrekwentie werd gemeten in wakkere ratten en de in 
vitro of intrinsieke hartfrekwentie in ge"isoleerde harten. Onbehandelde infarct ratten 
werden gekenmerkt door een opmerkelijke in vivo tachycardie en toename in 
intrinsieke hartfrekwentie. Vroege behandeling met aspirine, methylprednisolone en 
moxonidine resulteerde, in tegenstelling tot captopril,in een verlaging van postinfarct 
in vivo tachycardie. De toename in intrinsieke hartfrekwentie na myocardinfarct kon 
gereduceerd worden met vroege aspirine en methylprednisolone behandeling maar 
niet met captopril en moxonidine. In deze vergelijkende studie werd tevens 
aangetoond dat preventie van linker ventrikel hypertrofie gepaard gaat met 
normalisatie van de capillaire dichteid zonder de hoeveelheid capillairen te 
beTnvloeden (in geval van moxonidine en captopril behandeling), en dat vroege 
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aspirine en methylprednisolone behandeling de capillaire dichteid kan normaliseren 
als gevolg van effectieve capillaire groei. Er werd geconcludeerd dat normalisatie van 
intrinsieke (in geval van aspirine en methylprednisolone) eerder dan in vivo 
tachycardie na myocardinfarct een mogelijk mechanisme is om capillaire groei in 
ge"infarceerde harten te stimuleren. 
In hoofdstuk 7 werd de algemene discussie met conclusies en implicaties voor de 
toekomst beschreven. Gebaseerd op de resultaten van deze thesis werd 
geconcludeerd dat vroege behandeling na myocardinfarct zich niet Iauter mag 
focuseren op remming van het remodeling proces. Het vereist een subtiele en 
specifieke interferentie met het remodeling proces teneinde de functie van het 
falende hart te verbeteren. Vroege interferentie met het postinfarct remodeling 
proces dient niet gefocuseerd te zijn op de remming van compensatoire hypertrofie, 
maar eerder op behoud van totaal weefsel en stimulatie van capillaire groei. Aile 
vroege behandelingen die reactieve hypertrofie na myocardinfarct remden, konden 
afgezien van een herstelde capillaire dichtheid, de hartfunctie niet echt verbeteren. 
In dit proefschrift werd tevens aangetoond dat capillaire groei in het niet-
ge"infarceerde myocard als gevolg van een gereduceerde intrinsieke eerder dan in 
vivo tachycardie, resulteerde in verbetering van de hemodynamiek (aspirine en 
methylprednisolone). Nochtans bleek duidelijk uit de resultaten van vroege 
behandeling met de V1A vasopressine antagonist dat nag andere mechanismen 
onafhankelijk van capillaire groei een belangrijke rol spelen in de verbetering van de 
functie van het falende hart. Naast de effecten van vroege behandeling op de 
hypertrofie en capillaire groei, werd aangetoond dat farmacologische interferentie 
met de collageenafzetting een belangrijk effect heeft op diastole hartfunctie en 
actieve relaxatie van de hartspier. Tot slot kunnen we in overeenstemming met onze 
vooropgestelde hypothese en resultaten besluiten dat vroege farmacologische 
interferentie met het postinfarct remodeling proces dient gericht te zijn op het 
behoud van de hoeveelheid cont@ctiel weefsel en stimulatie van vaatgroei teneinde 
de functie van het falende hart te verbeteren. 
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M yocardial infarction is a leading cause of heart failure. The neurohormonal hypothesis postulates that neurohormones are initially adaptive by maintaining 
cardiac output and blood pressure, but later the same 
compensatory responses become pathological and contribute to 
adverse remodeling, progressive ventricular failure, and ulfimatly 
to the syndrome of heart failure. In the past, pharmacological 
research has mainly focused on the relief of symptoms when 
congestive heart failure is diagnosed and prognosis becomes 
very poor. Except for treatment with angiotensin converting 
enzyme inhibitors, prognosis has not benefited substantially from 
all these research. Instead of aiming the regression of remodeling 
in the late phase, therapy early after myocardial infarction can 
be an alternative approach to prevent heart failure, but may 
include strong interference with the cardiac remodeling process. 
The aim of this thesis was to investigate the effects of 
pharmacological interference with the different aspects of 
postinfarcfion remodeling during the early compensatory 
stage in an experimental heart failure model. The findings 
of this thesis confirm our hypothesis that early treatment 
after myocardial infarction should not simply prevent cardiac 
remodeling. If requires subtle and specific interference 
with the remodeling process in order to improve 
contractile function of the failing heart. 
